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Discovery and Development of a Three-Component Oxidopyrylium Cycloaddition and Its 
Application Towards α-Hydroxytropolone Synthesis  
by 
Michael P. D’Erasmo 
Advisor: Professor Ryan P. Murelli  
Historically, natural products have provided unique research opportunities and challenges 
for organic synthesis, chemical biology, and medicinal chemistry due to their molecular 
complexity and effects on physiological systems. The total synthesis of natural products has not 
only produced novel reaction methods and strategies capable of efficiently generating complex 
structural motifs but also granted access to sufficient quantities of otherwise scarce natural 
product material for clinical evaluation. These synthetic efforts have facilitated the formation of 
a transdisciplinary partnership between chemistry, biology, and medicine that has been 
paramount in elucidating the chemical and pharmaceutical utility of natural products. Chapter I 
of this thesis will highlight several key examples of how natural products inspired synthetic 
methodology, small molecule drug and probe development, and the discovery of previously 
unknown biologically active scaffolds. A particular focus will be spent on the synthetic and 
biological endeavors made by our laboratory involving α-hydroxytropolones (αHTs).  
  αHTs are a subclass of troponoid natural products that possess promising activity 
against a broad range of therapeutically significant targets. In order to gain access to these 
molecules, our laboratory utilizes an oxidopyrylium cycloaddition/ring-opening strategy. During 
our synthetic investigations, we recently discovered a three-component oxidopyrylium 
cycloaddition that generates novel 8-oxabicyclo[3,2,1]octene products. In Chapter II, the 
v  
development and optimization of this synthetic method towards the construction of a library of 
new oxabicyclic species will be detailed. Initial attempts at applying the reaction towards αHT 
synthesis will also be discussed, as a tandem debenzylation/ring-opening procedure with benzyl-
derived oxabicyclic intermediates is outlined. Further exploration of the utility of the three-
component oxidopyrylium cycloaddition will be described in Chapter III and Chapter IV, as 
the first solid-phase and fluorous syntheses of αHTs are reported, respectively. The advantages 
and disadvantages of each strategy will be considered in these chapters, specifically pertaining to 
the efficiency of purification, incorporation/cleavage of solid-phase resins and fluorous tags, and 
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The identity of an individual is molded by life experience and the teachings obtained 
from family and friends. At this point in my life, there are several principles I hold very dear to 
my heart, including: 1) hard work and determination are pivotal for success, 2) treat all living 
creatures the way you want to be treated, and 3) always pursue the truth no matter how difficult 
it may be to accept. My perspective on the world has changed drastically by trying to apply these 
principles in my daily actions and aspirations for the future. With hard work and determination, I 
have come one step closer with the writing of this thesis to achieving my dream of making 
scientific contributions to humanity’s knowledge regarding neurodegenerative diseases. Coming 
from a position of respect and dignity for all life, I have learned to consider the impact of my 
actions and words on people, animals, and the environment. By placing the truth above all else, I 
have continued to develop a belief system devoid of hypocrisy and baselessness. What I have 
described may sound cliché or obvious to many individuals out there, but in order to be instilled 
with such concepts and principles, experience and mentorship are required. I would like to 
devote some time in showing appreciation to all those people that have taught me the importance 
of these principles and got me to this point in my career.   
Since I was a child, my favorite topics in school were math and science. I often cracked 
open books describing the characteristics and anatomy of bugs, particularly spiders, and brought 
them to school for everyone to see. Despite being known as the bug boy by all my teachers and 
classmates, whenever I was asked what I wanted to be throughout grade school, I never 
considered a career in science. It was not until my junior and senior years at Mount Saint 
Michael Academy that I developed a love for chemistry. My interest in the field would not have 
emerged if it were not for my chemistry teacher, Mr. Manton, who always found a way to make 
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the topics interesting, challenging, and fun. I thank him for the experiences I had in his honors 
and AP classes, along with his guidance and support, which pushed me to seek a college degree 
in chemistry.  
At Fordham University, I wanted to take as many science classes as possible to satisfy 
my curiosity and hunger for knowledge. However, I had no clue where a chemistry degree could 
take me outside of patent law, which was unappealing to me at the time. Fortunately, I met 
several professors who provided me with the inspiration to seek a doctorate in chemistry and 
sparked my interest in drug research and development. Most of all, I would like to thank Prof. 
John J. McMahon for giving me the opportunity to work in his laboratory as an undergraduate. 
Without his mentorship and encouragement throughout those years, I would have never 
appreciated the importance of chemistry research nor seen its potential applications outside of 
academia. I cannot thank him enough for the doors he has opened and the guidance he has given 
during my times of uncertainty. I would also like to thank Prof. Ipsita Banerjee for inspiring me 
to pursue a career in medicinal chemistry. With her excellent biochemistry classes, I became 
extremely interested in drug discovery and development, especially as it relates to 
neurodegenerative processes. Due to her constant advice and support, I decided to travel the path 
of a medicinal chemist and I am very grateful. Lastly, I would like to thank Prof. Christopher 
Bender for all of his assistance and instruction on many career and life matters, specifically 
relating to choosing a mentor. Due to the experiences and real-world perspective he shared, I 
made sure to carefully assess which individual I would work for during my graduate studies.  
Though I decided to embark on the journey towards an advanced chemistry degree, I 
became fatigued with classes and lost hope with finding an appropriate environment to do 
scientific research. I ended up at The Graduate Center where I met the people who impacted my 
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life the most outside my family. To begin, I would like to thank Prof. Mark R. Biscoe, Prof. 
Stacey Brenner-Moyer, and Prof. Maria Contel for all their support and guidance over the years. 
Not only have their excellent chemistry classes sparked my interest in the field again, but they all 
gave me the chance to do rotations in their laboratories that helped immensely in refreshing my 
knowledge of common techniques and overcoming research jitters. I would also like to thank my 
committee members, Prof. Emilio Gallicchio, Prof. Guillermo Gerona-Navarro, and Prof. David 
R. Mootoo, for all their assistance, insight, and suggestions relating to research projects. Due to 
the challenges and questions I encountered in the meetings with them, I have learned a great deal 
about what it takes to formulate and convey an independent research project. Finally, I would 
like to thank Prof. Ryan P. Murelli for everything he has done. For five years, he has provided 
tremendous support and mentorship, and I am extremely grateful. I think the first meeting we 
ever had was at Science Day in The Graduate Center, where his excitement level was at a 
maximum while describing his research. When I needed to make the difficult decision of 
choosing a laboratory, his eagerness and ability to explain his scientific vision was what 
persuaded me to join his group. It has been an honor contributing to that vision, and I will 
cherish the memories I have in his laboratory.  
Upon entering a research intensive program after being out of the laboratory for years, I 
was very nervous about being properly equipped with the skills to handle myself. Fortunately, I 
took advantage of the rotation requirements at The Graduate Center and came in contact with 
incredible senior students. I especially want to thank Dr. Malgorzata Frik, Dr. Josh Jones, Dr. 
Ashwini Ghogare, and Dr. Christine Meck for the patience, support, and guidance they provided 
throughout my studies. Their suggestions and insight relating to research and the graduate 
program in general assisted me greatly in overcoming initial reservations and anxiety. I have 
nothing but respect for them, and I appreciate all they have done.  
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Though very rewarding at times, the graduate school experience can be nightmarish. 
When you are stuck in the laboratory all day for most of the week, you are broken down both 
physically and emotionally, especially if a project is not going the right way. Luckily, I had the 
benefit of being surrounded by very supportive colleagues during my time in the Murelli 
laboratory to deal with the graduate roller coaster. At the top of the list, I want to acknowledge 
Danielle Hirsch who has been a fellow soldier in the trenches since the beginning of the 
program. She has not only been a great coworker but a true friend throughout the years. She is an 
extremely competent and skillful scientist, and I am certain success will follow her wherever she 
goes in the future. Outside all of that, she has demonstrated a kind, compassionate, and 
trustworthy personality that I think is very difficult to find. To me, she has been a very influential 
force on real-world topics, especially animal welfare and veganism. Due to our conversations on 
such issues, I have learned to better appreciate animal life, whether it is a dog in the house or a 
pig on the farm, and apply that respect more generally through my diet by becoming a 
vegetarian. I have also had the privilege of being introduced to the many animal friends that are a 
big part of her life, such as her angel Goldendoodle, Marley, majestic horse, Haley, handsome 
pony, Shadow, and spastic turtle, Turtle. I thank her for the times we have shared together, and I 
will cherish all of the experiences and memories. I would also like to thank Alex Berkowitz for 
being the wiseguy of the laboratory. I could not have made it through the day without his jokes 
about my Bronx accent. Beyond that, he has been a good friend and a positive force for the 
group. There have been many days that he has refreshed my memory or taught me something 
new on chemistry related topics. He has the potential to run his own laboratory one day, and I 
await the day that it happens. I would like to thank Daniel “Staniel” Schiavone for having one of 
the best personalities an individual can have. His uniqueness can only be experienced in person, 
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and I feel bad for those of you who are reading this and have not. He is an extremely 
hardworking and intelligent scientist, and I know he will be an inspiration for the generations to 
come. The same can be said about Lauren Bejcek, who I thank for introducing the essence of 
Chicago to the Murelli laboratory. Because of her, I would visit the city just to get a taste of Lou 
Malnati’s deep dish pizza and meet her distinguished dog, Sir Edward II. She has loads of 
potential as a chemist, and I look forward to seeing what she accomplishes. I would like to thank 
John Stasiak for his never-ending positivity throughout the day. I do not think I have ever seen 
him express rage at a person or an extremely negative outlook on a subject. His personality has 
been refreshing, especially in such an emotionally taxing field. His intelligence, work ethic, and 
positivity are bound to bring him prosperity. I would like to thank Nana Agyemang and Irina 
Kashis for their insight on career and life issues. During graduate school, you are often 
bombarded with questions concerning your future directions and goals that create doubt and 
hesitation. Their wisdom and realistic perspective continues to help me overcome many 
uncertainties or fears about the future path. Both of them are headed for success, and I appreciate 
the support and advice they have given to me. Lastly, I would like to thank Sarah Avidan, Errol 
Hunte, and Duygu Suyabatmaz for all of the experiences and memories. It was a privilege being 
a part of key events in Sarah’s life, such as her wedding and the birth of her child, Abraham. I 
will always remember the fiery and curious nature of Duygu, and the antics we would get into in 
the laboratory. I thoroughly enjoyed the philosophical discussions I had with Errol on topics 
ranging from politics to anime. All of them are extremely smart and hardworking individuals, 
and I know they will succeed in their future endeavors.  
 Even though a majority of your time in graduate school is spent in the laboratory 
discovering the unknown or trying to get reactions to work, I had the opportunity to explore 
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outside my research and meet some incredible classmates, future scientists, and professors. I had 
the pleasure of meeting Gan Zhang, Niccole Fuhr, Andy Lu, Niluksha Walalawela, Jiye Son, 
Vincent Mui, Dr. Jacob Fernández-Gallardo, Dr. Flavia Barragán, Dr. Americo Fraboni, Marek 
Wlodarczyk, Khadija Wilson, Dajana Alku, Yoko Bian, Dr. Stephen Chester, Dr. James 
Aramini, and many more. I could probably write a book outlining all of the fun times and 
conversations I had with these individuals. However, for the sake of brevity, I would like to 
thank all of them for making the graduate experience brighter and more epic.  
 Of course, I would not have gotten to this point in my career if it were not for the support 
and guidance from my family and friends. Most of all, I want to thank my parents, Debra and 
Frank D’Erasmo, for everything they have provided. I would not be the man I am today if it were 
not for the lessons and opportunities they have given me. Since I was a child, my dad has always 
been an inspiration and role model. He has taught me the principles of hard work, respecting 
others, and pursuing a dream no matter how tough the road gets. My mom has been a key source 
of support and mentorship throughout my life. I would not have learned the value of education if 
she did not push me as a child and beyond. They have sacrificed a lot to get me here, and I am 
eternally grateful. I would also like to thank my brothers, Jerry and Frank D’Erasmo, for their 
constant support and life-changing advice. They have exposed me to many new things, ranging 
from music to nutritional guidelines, which have shaped who I am as an individual. Many of the 
viewpoints I have of the world emerged from their influence, and I would not change them for 
anything. I would like to acknowledge my grandfather, Jerry Cuomo, who passed away during 
my doctorate studies. He always served as a pillar of strength for our family as a whole, and 
stopped at nothing to bring everyone together. His work ethic, compassion, and kindness were an 
inspiration to everyone, and he is sorely missed. I would like to thank the many friends who have 
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brightened up my life and supported me along the way. Specifically, I want to acknowledge Min 
Hur and Michael “Naps” Napolitano for being brothers from other mothers, and Vinny Rinaldi, 
Agostino Conte, and many others for all the great times we had together. Last and best of all, I 
want to acknowledge all the furry friends that I hold dear to my heart, such as Spike, Boomer, 
Bruiser, Rowzer, Scarlett, and R. J. These bundles of joy have impacted my life immeasurably, 
and words cannot express their importance to me. 
 On a final note, the next step for me is a trip to Emory University to work for Prof. 
Dennis Liotta. Every individual I have acknowledged has played a role in getting me to this 
point. To that end, I would like to thank our collaborators Prof. John Tavis, Prof. Lynda 
Morrison, Dr. John Beutler, Dr. Stuart Le Grice, Dr. Jay Bradner, Prof. Gerry Wright, and others 
for their hard work on the medicinal chemistry studies. I would also like to thank the financial 
support from the National Institutes of Health (SC2GM09959 and SC1GM111158) for making 
this graduate research possible. Finally, I would like to thank Prof. Brian Gibney for allowing me 
to speak in front of Prof. Liotta at The Graduate Center, which opened the door for the following 
job interview. I am very grateful for this opportunity, as it is another step towards achieving my 
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Chapter I  
Exploring Nature’s Bounty: The Indispensable Partnership Between 
Chemistry, Biology, and Medicine 
1.1. Introduction  
Investigating nature’s molecular diversity and its effects on physiological systems 
continues to be a central area of advancement and cooperation for chemistry, medicine, and 
biology.
1
 Each natural product class isolated and characterized possesses unique three-
dimensional construction and biological properties that introduces original research opportunities 
and challenges.
2
 These compounds typically demonstrate structural domains very similar to 
many human macromolecules, which provide intense pharmacological activity and selectivity.
2,3
 
Hence, natural products are by far the most abundant source of new small molecule drugs,
4 
with 
penicillin V (1.1, antibiotic), artemisinin (1.2, antimalarial), and galantamine (1.3, Alzheimer’s 
treatment) being only a few examples (Figure 1.1). Additionally, such molecules have the 
capability to efficiently modulate biomolecular function, making them exemplary probes to 
systematically analyze cellular components, biochemical events, and signaling pathways.
2,5




1.2. (+)-Discodermolide: Total Synthesis Leading to Clinical Development 
 Historically, the total synthesis of natural products has brought about novel reaction 
methods and technologies, innovative strategies for the rapid creation of complex structural 
motifs, and a broad range of biologically active analogs derived from the targeted molecules.
2
 
Such breakthroughs have facilitated significant strides in the synthesis and modification of drugs 
by enabling the production of sufficient quantities of scarce natural product material for clinical 
development. As a result of these efforts by organic chemists, pharmaceutical endeavors 
spanning both academia and industry emphasize the use of natural product isolation and organic 
synthetic techniques in the design, generation, and testing of small molecule inhibitors and 
chemical probes.
1,2
 This combination between organic synthesis and biology has unraveled 
fundamental information on many physiological systems and established the standard for drug 
discovery and development.  
 For example, (+)-discodermolide (1.4) is a polyketide natural product first isolated in 
1990 by Gunasekera and co-workers from the Carribbean deep-sea marine sponge Discodermia 
dissoluta.
6
 Similar to paclitaxel (1.5, Taxol
®
) and epothilones (1.6), the molecule inhibits 
proliferation of cancer cells by stabilizing microtubules and arresting the cell cycle prior to 
mitosis (Figure 1.2).
7
 Additionally, (+)-discodermolide possesses a number of other unique 
biological characteristics, including immunosuppression both in vitro and in vivo,
8
 potent 
acceleration of cell aging,
9
 synergistic anticancer activity with paclitaxel,
10
 and neuroprotective 
effects.
11
 Due to its promising biological profile, the pharmaceutical industry was extremely 
interested in clinically evaluating the natural product. However, since (+)-discodermolide 
accounts for only 0.002 wt.% of D. dissoluta
6
 and all efforts to cultivate this organism failed, 
material management restricted the advancement of biological studies. Such a supply dilemma 
3  
made (+)-discodermolide an attractive target for total synthesis, and thus organic chemists sought 
to develop a scalable synthetic route to generate its complex structure. 
In 1993, Schreiber and co-workers described the first total synthesis of the unnatural 
enantiomer (-)-discodermolide, which proved useful in establishing the absolute stereochemistry 
of the natural product.
12
 After this study, a number of unique approaches emerged from academia 
and industry detailing the synthesis of both discodermolide enantiomers.
13
 A retrosynthetic 
analysis of these total syntheses reveals that all of them deconstruct the natural product into three 
major fragments, each of which contain the contiguous methyl-hydroxyl-methyl array of 
stereogenic centers present in the target molecule (Figure 1.3 for select examples). Various 
strategies were then employed to couple the segments with the appropriate configuration and 
stereochemistry, including the Nozaki-Hiyama-Kishi coupling/enol alkylation approach of 
Schreiber,
12,14
 the Negishi coupling/Wittig olefination route of Smith,
15
 and the novel chelation-




As the synthetic research became more extensive, focus shifted towards making the 
reaction sequences shorter, more convergent, and more practical in order to produce the material 
demand required for clinical development.
13
 Novartis Pharma AG took inspiration from these 
methods and described a 39-step synthesis of 60 g of (+)-discodermolide in 2004 (Scheme 
1.1).
17
 Specifically, Novartis integrated the Smith common precursor 1.18 to produce the three 
major fragments and the Paterson aldol chemistry to connect the final segments together. The 
material generated proved to be sufficient in advancing (+)-discodermolide to early-stage human 
clinical trials. In addition, these synthetic developments facilitated the creation of a number of 
5  
research programs aimed at the design, synthesis, and evaluation of (+)-discodermolide 
analogs.
13
 Such efforts have uncovered the binding elements required for the natural product’s 
biological profile and enabled the rational design of more potent anticancer agents through in-
depth structure-activity relationship (SAR) studies. 
1.3. (-)-Diazonamide A: Chemical Probe Synthesis Elucidating Biological Pathways 
Alongside its pivotal role in drug discovery, synthetic research geared towards the 
assembly and modification of biologically interesting natural products has elucidated key 
mechanistic information on many physiological processes through chemical probe 
development.
1,2,18
 For instance, (-)-diazonamide A (1.20, Figure 1.4), a compound isolated from 
6  
the colonial marine ascidian Diazona angulata, became an extremely popular target for organic 
chemists and the pharmaceutical industry due to its intriguing molecular structure and potent 
cytotoxicity against a variety of human cancer cell lines.
19
 Early reports indicated that the 
compound’s activity emerged from its microtubule-binding ability.
20
 However, other studies 
contradicted this hypothesis, demonstrating that (-)-diazonamide A does not compete with 
known tubulin-binding agents, such as maytansine (1.21) or vinblastine (1.22, Figure 1.4).
21a
 
Thus, the race was on for a practical total synthetic route to access the molecule and its analogs 
for biological evaluation.  
By the late 1990s, nearly a dozen research groups dedicated efforts at efficiently 
synthesizing (-)-diazonamide A.
22
 These ventures encountered a roadblock when Harran and co-
workers in 2001 made the surprising discovery that the originally proposed structure for the 
natural product had been misassigned based on their synthesis of 1.23 and 1.24 (Figure 1.5).
23
 
Re-evaluation of the spectroscopic and crystallographic data acquired on (-)-diazonamides 
revealed that the molecule actually possesses diarylaminal motifs instead of the phenolic 
hemiacetals suggested from initial studies. Following these conclusions, attention was directed  
 
7  
towards generating the new structure, as a number of total syntheses on diazonamide A would 
emerge in the literature.
22
 However, the synthetic strategy that became the most relevant in the  
clinical progression of diazonamides as chemotherapeutic agents would originate from Harran 
and co-workers in 2003.
24
 
The Harran 19-step approach to diazonamide A (1% overall yield) consisted of 
constructing a seco-peptidyl precursor and installing the primary diarylaminal core through 
oxidative annulation of the tethered tryptophan and tyrosine side chains (1.26 → 1.28, Scheme 
1.2).
24
 Also, the atropisomerism in the eastern region of the molecule was established with a 
photoinduced electron transfer reaction under basic conditions (1.29 → 1.32). Using this route to 
assemble a biotinylated derivative, Harran, Wang, and co-workers disseminated the 
mitochondrial enzyme, ornithine δ-amino transferase (OAT), as the biological target for the 
natural product.
21
 These mechanistic studies also suggested that OAT serves an important 
function in mitotic cell division, bringing to light a potential target for anticancer drug 
development. More recently, the Harran synthetic method has been utilized and advanced in 
collaboration with the pharmaceutical industry to produce detailed SAR studies on diazonamides 
and potent antimitotic agents poised to enter clinical trials.
25 
8  
1.4. Vancomycin and Teicoplanin: Confronting Chemical and Biological Challenges with 
Synthetic Methodology  
As outlined earlier, since physiologically active natural products are already equipped 
with structural characteristics that efficiently bind to the domains of biological macromolecules, 
they provide an ideal canvass for the semisynthesis of promising drug derivatives and chemical 
probes.
1,2,18
 However, direct chemical alteration of natural products can be extremely difficult 
due to the presence of multiple functional groups and stereogenic centers, which limit reaction 
efficiency and selectivity. To address the challenge of natural product reactivity and the 
increasing demand for SAR studies based on semisynthetic modification, sophisticated 
developments on the synthetic methodology front have emerged.
2,26
 In particular, site-selective 
functionalization has become an effective tool in the synthesis of natural products and their 
corresponding analogs.  
9  
For example, Miller and co-workers have demonstrated the site-selective bromination of 
the glycopeptide antibiotics, vancomycin (1.33) and teicoplanin (1.36), using peptide-based 
catalysts.
27
 In the study involving vancomycin, the research group reported that the inherent 
reactivity of the natural product towards halogenation can be controlled depending on the 
additives present (Figure 1.6).
27a
 On one hand, taking inspiration from the antibiotic’s natural 
binding mode to bacterial cell walls,
28
 peptide 1.34 was designed and used to accelerate the 
selective bromination of vancomycin at the 7f position. On the other hand, in order to reverse the 
site of functionalization to the 7d position, guanidine-HCl (1.35) was the additive of choice 
because of its capability to interact with the free carboxylate functionality and speed up 
bromination reactions.
29 
Miller and co-workers would then apply these results to teicoplanin compound 1.36, 
which possesses increased biological activity and molecular diversity compared to vancomycin 
(Figure 1.7).
27b
 Not only was peptide-dependent bromination at either the 5,7-biaryl or 1,3-biaryl 
10  
ether sectors of the molecule achieved, but the group also performed Suzuki cross-coupling on 
the brominated derivatives using aqueous conditions (i.e. Pd(OAc)2/sSPhos). This chemistry 
enabled the direct synthesis of eleven novel teicoplanin analogs previously unavailable through 
biosynthesis or total synthesis. Evaluation of the new compounds against a variety of bacterial 
strains revealed comparable or increased activity in relation to vancomycin and teicoplanin. 
Thus, the Miller site-selective bromination has the potential to grant access to a library of unique 
natural product derived antibiotics useful against the rising threat of glycopeptide-resistant 
bacteria. 
1.5. γ-Hydroxybutenolides: New Chemical Entities Generated from Natural Product 
Synthons 
 The progression and cooperation of organic synthesis, structural biology, and medicinal 
chemistry has yielded technologies and methods to determine the primary components 
responsible for the biological activity of natural products (i.e. pharmacophores).
1,2,18
 As a result, 
11  
considerable attention has been directed towards the development of synthetic methods capable 
of preparing these structural moieties. Generally, these studies produce greatly simplified 
analogs that mimic or exceed the function of the natural product from which they were 
inspired.
2,18
 However, depending on the synthon’s reactivity, it is possible to generate completely 
new chemical entities with promising pharmacological properties.  
For instance, γ-hydroxybutenolides are heterocyclic motifs present in a variety of 
biologically interesting natural products (Figure 1.8).
30
 These structures are readily synthesized 
through the oxidation of furan
31
 and serve as synthetic precursors to elaborate lactone-containing 
derivatives.
32
 Moreover, reports on γ-hydroxybutenolide reactivity have demonstrated that these 
molecules actively engage in cascade and cycloaddition reactions
32




1.5.1. The Discovery of Novel Spirocyclic Ketal-Lactones  
Considering their ease of preparation and capability to form intricate constructs through 
multi-bond forming processes, our laboratory further investigated γ-hydroxybutenolide 
chemistry.
34 
These studies, conducted by Alberto Munoz, illustrated that 
γ-methyl-γ-hydroxybutenolide (1.40) reacts with aromatic aldehydes in the presence of triflate-
12  
based acids (e.g. triflic acid or trimethylsilyl triflate) to produce new spirocyclic ketal-lactones 
(1.44, Scheme 1.3). An inspection of the substrate scope determined that electronically poor 
aromatic aldehydes provide the highest yields (e.g. 1.44a-c), as more electron rich aromatic and 
aliphatic species require large excesses of reagent to force conversion or lead to little or no 
incorporation (1.44d-f). Lastly, γ-methyl-γ-hydroxybutenolide can be replaced with the γ-ethyl 
derivative, supplying a molecule with 4 stereogenic centers (1.44g).  
 Our proposed mechanism for the process involves an elimination/Prins cascade, whereby 
the lactone 1.41 forms in situ under acidic conditions and undergoes a reaction with 2 equiv. of 
aldehyde to generate the spirocyclic ketal-lactones (Scheme 1.3). Butenolide 1.41 is also known 
as protonanemonin, which is a toxic metabolite found in the Ranunculaceae plant family
35
 and 
synthon that efficiently performs Diels-Alder and dipolar cycloaddition reactions.
36
 Supported by 
NMR experiments and crystallographic data, the transformation demonstrates reversibility at the 
steps that introduce relative stereochemistry and exhibits high diastereoselectivity that is 
13  
thermodynamically driven. Additionally, partial incorporation was observed after selected 
spirocycles were re-subjected to reaction conditions with aromatic aldehydes, providing further 
evidence for the reversibility of the process (Scheme 1.4).
34
 
1.5.2. Biological Evaluation of Novel Spirocyclic Ketal-Lactones  
With rapid access to a series of unprecedented spirocyclic diaryl butenolides that contain 
an ‘extended ketal-lactone’ moiety present in many well-established bioactive molecules (Figure 
1.9),
37
 we directed our attention towards assessing the pharmaceutical utility of the novel 
constructs. In collaboration with the Bradner group, the compounds we generated were evaluated 
for anticancer activity through a previously reported 48-hour viability assay.
38
 These experiments 
uncovered that the butenolides illustrate potent cytotoxicity against a T-cell lymphoma cell line 
(MJ) and a very aggressive epithelial cancer cell line (797 NUT midline carcinoma or NMC). 
Moreover, the cytotoxic behavior of the molecules appears to be limited to mammalian cells, as 
no noticeable growth inhibition was observed in Gram-negative bacteria assays. 
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Our structure-function study revealed that spirocyclic butenolides with electron-
withdrawing functionalities on the phenyl appendages possessed the greatest potency (1.44a, 
Figure 1.10). When the electron-withdrawing groups or the aromatic rings were removed, the 
activity was severely reduced (1.44d, 1.44f). Diminished cytotoxicity also occurred when a 
methyl substituent was added to the dioxane ring (1.44g). Additionally, when the size of the 
aromatic appendages was extended, as shown with derivatives 1.44j and 1.44k, the inhibition 
was negatively impacted. Thus, the information obtained illustrates that the spirocyclic 
butenolide core is responsible for cytotoxicity, while the aromatic functionalities increase 
potency. Though electron poor appendages yield the greatest inhibition, the activity is influenced 
by a size restriction. Unfortunately, due to the limitations of the synthetic method outlined above, 
a more diverse array of electronically rich aldehydes could not be examined. 
We next tested if the pseudosymmetry of spirocyclic butenolides 1.44h and 1.44i had any 
effect on biological activity (Figure 1.10). Despite differing merely in the position of the nitro 
group, the compounds possessed nearly identical potency against the NMC and MJ carcinomas 
and were approximately half as active as 1.44a. With regard to the binding mode of these 
molecules, this data suggests that one aromatic ring does not have more control than the other. 
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Two possibilities emerge as a result: 1) the aromatic substituents work in combination during 
binding or 2) one group is responsible for interacting but the pseudosymmetry of the molecules 
makes each enantiomeric form roughly equivalent in potency.  Our current methods do not allow 
for the enantioenrichment of the spirocycles to prove which hypothesis is correct. Nonetheless, 
efforts are currently being dedicated towards studying the mode in which the aromatic 
appendages induce increased potency to the butenolide analogs.  
Finally, we tested whether or not the electrophilic alkene on the butenolide core was 




 the possibility that the spirocyclic structures are covalent modifiers exists. 
Therefore, compound 1.48b was synthesized by reducing 1.44b with Pd/C under a hydrogen 
atmosphere (Scheme 1.5). The newly made molecule demonstrated no cytotoxicity, indicating 
that the spirocyclic butenolides are covalent inhibitors.      
In summary, natural product scaffolds can lead to new chemical entities with promising 
physiological properties. Our laboratory has discovered a novel synthetic method to synthesize a 
previously unknown class of spirocyclic ketal-lactones. Subsequently, we reported that these 
molecules are potent cytotoxic agents against NMC797 and MJ carcinomas, outlining an in-
depth structure-function study on their biological activity.  
1.6. α-Hydroxytropolones: Natural Product ‘Privileged Scaffolds’ Inspiring Clinically 
Effective Drug Libraries  
 Many physiologically active natural products contain ‘privileged substructures’ that have 
been molded by evolutionary processes to bind to a variety of receptors and enzymes.
2,18,40
 
Coined by the Evans group in their 1988 pharmacological study of benzodiazepines,
41
 a 
‘privileged scaffold’ is applied to molecular constructs with the binding versatility and potential 
to provide ligands for a wide range of biological macromolecules. It is surmised that these 
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compounds achieve such promiscuous binding through mimicry of typical biomolecular surface 
elements, such β- and γ-turns in proteins.
40
 Considering their synthesis and modification are 
directed by physiological mechanisms and their function might involve completely different 
cellular pathways, a plethora of natural product classes embody this concept (Figure 1.11 for 
examples). 
Due to their promising bioactivity, a number of research programs have dedicated efforts 
at synthesizing compound libraries based on natural product-derived privileged structures.
18,40
 
The strategies reported provide quick access to novel chemical entities through the alteration of a 
central core framework and side-chain optimization. Additionally, the resulting privileged 
constructs typically exhibit favorable drug-like characteristics, allowing for the discovery and 
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development of new lead molecules for multiple receptors. For example, Nicolaou and co-
workers have detailed the combinatorial synthesis of a 10,000-member benzopyran library using 
a traceless phenylselenium resin.
42
 Biological studies on the compound collection revealed a 
high hit rate, with some molecules inhibiting hypoxic activation of tumor growth.
43
 Overall, 
rational drug design based on privileged structures can be beneficial to the drug discovery 
process and improve the effectiveness of biologically active species.  
Our laboratory focuses on another privileged class of molecules, α-hydroxytropolones 
(αHTs). These compounds are a subset of troponoid natural products that possess therapeutic 
potential against a wide variety of biological targets (Figure 1.12).
44
 Pharmacological studies on 
β-thujaplicinol (1.58) and manicol (1.59) have revealed that αHTs exhibit promising activity 
against human immunodeficiency virus (HIV),
45
 hepatitis B virus (HBV),
46
 herpes simplex virus 
(HSV),
47
 and aminoglycoside resistant bacteria.
48
 Structurally, the molecules are defined by a 
non-benzenoid aromatic ring system with a contiguous array of three oxygen atoms (1.60, 
Figure 1.12B). Under basic conditions, this motif adopts a dianionic form (1.61), which can 
further resonate to a stabilized tropylium ion with significant negative charge localized on the 
oxygen assembly (1.62). Their promiscuous activity is generally attributed to the three 
contiguous oxygen atoms, which can bind to and inhibit an assortment of dinuclear 
metalloenzymes (represented by 1.62).
44
 The remaining positions on the αHT core can be 
manipulated to increase enzymatic potency and selectivity. Thus, αHTs are appealing scaffolds 
for developing new drug leads against several therapeutically challenging diseases. 
1.6.1. Oxidopyrylium Cycloaddition/Ring-Opening Route to αHTs 
Despite the promising inhibitory profile of this natural product class, the number of 
synthetic methods available to access αHTs and SAR studies probing their bioactivity is 
lacking.
44
 Motivated by the deficiency in synthetic and medicinal chemistry developments, our 
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laboratory invented a strategy to generate di- and trisubstituted αHT analogs utilizing 
8-oxabicyclo[3,2,1]octene intermediates (1.66, Scheme 1.6).
49
 In the two-phase approach, a 
3-hydroxy-4-pyrone-based oxidopyrylium cycloaddition gives the oxabicyclic compounds, 
which further undergo acid-mediated ring opening to αHTs (1.68). Among the advantages of our 
synthetic route are the use of readily available alkynes (1.65) and the facile introduction of 
structural diversity to the αHT core. Moreover, triflate salt 1.64, a key component of the 
oxidopyrylium cycloaddition step, can be made on a large-scale from kojic acid (1.63), which is 













Our synthetic method also grants access to more structurally complex αHTs through 
modification of the various reagents and intermediates. For instance, a series of ketone-
containing αHTs 1.68a-d was synthesized by initially performing oxidopyrylium cycloadditions 
between triflate salt 1.64a and ynone derivatives (1.70, Scheme 1.7). The ynones were generated 
using a previously described procedure, whereby the analogous acyl chlorides (1.69) are reacted 
with TMS acetylene in the presence of AlCl3.
51
 The resulting oxabicyclic compounds (1.66a-d) 
were then subjected to acid-mediated ring-opening/demethylation to yield the final products. 
1.6.2. Structure-Function Studies with Synthetic αHTs 
With this route in hand, our group was able to synthesize a sizable library of over 60 
αHTs and execute SAR studies on various pharmacological targets. In collaboration with several 










 and fungal pathogens.
56 
These biological studies present in-depth inhibitory 
information on the collection of αHTs, including the ketone-containing derivatives outlined in 
Scheme 1.7 (Table 1.1). However, the current discussion will focus on the significant HSV-
related discoveries made with the ketone-containing derivatives.
54
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HSV-1 and HSV-2 are highly related and ubiquitous human pathogens that have infected 
over half a billion individuals worldwide.
47,54,57
 The herpesviruses chronically infect mucosal 
surfaces and abraded skin and maintain a lifelong latency, whereby periodic reactivation of viral 
replication results in recurrent and transmissible diseases. HSV-1 is generally associated with 
cold sores, a rare form of encephalitis, and corneal blindness, while HSV-2 leads to genital 
ulcerative disease. In order to treat acute infections or reduce viral replication, nucleoside analog 
drugs such as acyclovir (ACV) are employed.
47,54,57,58
 However, the treatments are incompletely 
effective, and the emergence of drug-resistant viral variants is becoming an increasing threat, 
especially for immunocompromised patients.
47,54,57,59
 Thus, new molecules are required to 
achieve more efficient suppression of HSV.  
  HSV genomic replication relies upon numerous processes typically catalyzed by 
enzymes in the nuleotidyltransferase superfamily (NTS).
47,54
 These enzymes perform many 
functions in nucleic acid metabolism, including DNA and RNA digestion and DNA repair, 
integration and recombination. The NTS contains dinuclear metalloproteins, such as Human 
RNase H, HBV RNase H, HIV RNase H, and HIV integrase.
47,54,60
 Within their active sites, the 
enzymes possess three or four conserved carboxylates that coordinate two divalent cations 
pivotal for nucleic acid cleavage (Figure 1.13 for example). Tavis et al. demonstrated that 
compounds with the capability to suppress these enzymes, including β-thujaplicinol and manicol, 
could also inhibit wild-type and ACV-resistant HSV-1 and HSV-2 replication in cell culture.
47
 In 
collaboration with Tavis, Morrison, and co-workers, our laboratory then tested a series of αHTs 
against HSV to assess their viability as drug candidates.
54b 
The most potent molecule to emerge 
from the study was 1.68d, which exhibited nanomolar (nM) inhibition in HSV replication assays 
and displayed a synergistic therapeutic effect with ACV (Figure 1.14).  
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Subsequently, studies were conducted in order to identify the binding target for 1.68d. 
Based on NTS activity and homology, the αHT analog could interact with several possible HSV 
enzymes.
47,54
 One option is the pUL15 terminase, which is an end-stage RNase H-like divalent 
metalloprotein responsible for mobilizing viral DNA into the capsid.
61
 Inhibition and thermal 
stabilization experiments conducted in collaboration with Le Grice and co-workers illustrate that 
1.68d weakly binds to pUL15, indicating that the enzyme might not be the primary target of 
action.
54a
 A second choice is the exonuclease pUL12, which plays a role in DNA recombination 
earlier in the replication process.
62
 Initial experiments conducted with Weller and co-workers 
demonstrate that 1.68d interacts with pUL12. However, more data is required in order to obtain a 
complete mechanistic understanding.
54c
     
In summary, many natural product classes possess ‘privileged scaffolds’ that can interact 
with various therapeutically significant biomacromolecules. Designing compound libraries based 




Our laboratory has dedicated efforts towards synthesizing and biologically assessing αHTs, 
which bind to and inhibit an assortment of dinuclear metalloenzymes.
49,52-56
 During our 
screening of a 60 αHT library against a number of viral targets, we discovered the very potent 
HSV inhibitor 1.68d.
54
 Thus far, mechanistic studies have not fully elucidated the primary mode 
of action for the αHT derivative. However, biological studies aimed at identifying the viral target 
are currently ongoing. 
 
1.7. Conclusion 
 The drive to understand the structural complexity and physiological effects of natural 
products has led to incredible advancements across scientific disciplines. While exploring the 
chemistry of γ-hydroxybutenolides, a heterocyclic motif present in many biologically active 
molecules, our laboratory has discovered a synthetic method to access novel spirocyclic ketal 
lactones with potent cytotoxicity against the MJ T-cell lymphoma and NMC797 epithelial cancer 
24  
cell lines. Moreover, our group has invented a two-phase approach to generate 
α-hydroxytropolones, which are natural product-derived privileged substructures that possess 
activity against a wide range of therapeutically viable targets. This route has allowed us to 
construct a library of αHTs for several medicinal chemistry studies. Out of these efforts, we have 
reported highly potent synthetic analogs. One such example is 1.68d, a promising drug candidate 
with intense cellular activity against HSV. Utilizing this synthetic method, our laboratory 
continues to produce αHT analogs for pharmacological examination. The remainder of this thesis 
will highlight advancements made towards αHT synthesis. Specifically, herein will be described 
the discovery and development of a new three-component oxidopyrylium cycloaddition, and its 
application in the first solid-phase and fluorous-supported syntheses of αHTs.     
1.8. Experimental and Supporting Information 
General Information: All starting materials and reagents were purchased from commercially 
available sources and used without further purification, with exception of CH2Cl2, which was 




H NMR shifts are measured using 
the solvent residual peak as the internal standard (CHCl3 δ 7.26), and reported as follows: 
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet 
of doublet, q = quartet, m = multiplet), coupling constant (Hz), integration. 
13
C NMR shifts are 
measured using the solvent residual peak as the internal standard (CDCl3 δ 77.16), and reported 
as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong (s), 
medium (m), and weak (w). Mass spectra were recorded on a spectrometer by electrospray 
ionization (ESI) technique and time-of-flight (TOF) mass analyzer. Microwave reactions were 
performed via the Biotage
®
 Intiator (External IR Temperature Sensor). Where noted, reaction 
products were purified via silica gel chromatography using a Biotage
®
 Isolera Prime, with 
Biotage
®
 SNAP 10 g cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane.  
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Synthesis of Spirocyclic Ketal-Lactones: 
(5S,7R,9S)-7,9-bis(perfluorophenyl)-1,6,8-trioxaspiro[4.5]dec-3-en-2-one (1.44j).  To a 
solution of γ-hydroxybutenolide 1.40 (40 mg, 0.35 mmol) and pentafluorobenzaldehyde (866 μL, 
7.0 mmol, 20 equiv.) in CH2Cl2 (0.2 M, 1.75 mL) over 3Å molecular sieves (8 pellets) was 
added trimethylsilyltriflate (126 μL, 0.7 mmol, 2 equiv.). The reaction mixture was stirred for     
3 h, after which time Et3N (8 drops) was added. The reaction mixture was then immediately 
purified by column chromatography (silica (10 g), 2% EtOAc/hexane to 15% EtOAc/hexane 
gradient over 32 column volumes), giving 1.44j as a pale yellow oil (95.0 mg, 56% yield).        
Rf = 0.21 in 10% EtOAc in hexanes. IR (thin film, KBr): 3109 (w), 2935 (w), 2855 (w), 1787 
(s), 1657 (m), 1526 (s), 1514 (s), 1420 (m), 1304 (m), 1169 (s), 1139 (s), 1061 (m), 1017 (s), 976 




H NMR (400 MHz, CDCl3): δ 7.29 (d, J = 5.6 Hz, 1H), 6.61         
(s, 1H), 6.30 (d, J = 5.6 Hz, 1H), 5.74 (dd, J = 12.2, 2.3 Hz, 1H), 2.92 (t, J = 12.8 Hz, 1H), 1.93 
(dd,  J = 13.4, 2.5 Hz, 1H). 
13
C NMR (100 MHz, CDCl3): δ 168.8 (s), 152.0 (s), 147.0  – 146.4 
(m), 144.6 – 144.0 (m), 143.9 – 142.8 (m), 141.6 – 140.2 (m), 139.5 – 138.6 (m), 137.0 – 136.2 
(m), 124.7 (s), 112.1 – 111.5 (m), 110.7 – 110.2 (m), 105.1 (s), 92.0 (s), 67.6 (s), 35.2 (s). 
HRMS (ESI+): m/z calc’d for C19H6F10O4Na
+
: 510.9999.  Found: 511.0011. 
(5S,7R,9S)-7,9-bis(1-nitronaphthalen-2-yl)-1,6,8-trioxaspiro[4.5]dec-3-en-2-one (1.44k). To 
a solution of γ-hydroxybutenolide 1.40 (20 mg, 0.175 mmol) and 1-nitro-2-naphthaldehyde 
(211.2 mg, 1.05 mmol, 6 equiv.) in CH2Cl2 (0.2 M, 875 μL) over 3Å molecular sieves (4 pellets) 
was added trimethylsilyltriflate (63 μL, 0.35 mmol, 2 equiv.).  The reaction mixture was stirred 
for 1.5 h, after which time Et3N (4 drops) was added. The reaction mixture was then immediately 
purified by column chromatography (silica (10 g), 10% EtOAc/hexane to 33% EtOAc/hexane 
gradient over 30 column volumes), giving 1.44k as a brown oil (27.3 mg, 31% yield). Rf = 0.23 
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in 30% EtOAc in hexanes. IR (thin film, KBr): 3099 (w), 3066 (w), 2929 (w), 2877 (w), 1781 
(s), 1531 (s), 1359 (m), 1344 (m), 1200 (m), 1161 (m), 1140 (m), 1079 (w), 913 (m), 868 (w), 




H NMR (400 MHz, CDCl3): δ 8.05 (dd, J = 12.0, 8.7 Hz, 2H),         
7.98 – 7.87 (m, 2H), 7.82 – 7.71 (m, 4H), 7.69 – 7.58 (m, 4H), 7.23 (d, J = 5.6 Hz, 1H), 6.63    
(s, 1H), 6.29 (d, J = 5.6 Hz, 1H), 5.63 (dd, J = 11.6, 2.2 Hz, 1H), 2.57 – 2.45 (m, 1H), 2.20     
(dd, J = 13.6, 2.4 Hz, 1H). 
13
C NMR (100 MHz, CDCl3): δ 169.0, 151.8, 146.8, 146.1, 134.4, 
133.7, 131.9, 131.0, 129.2, 129.1, 128.8, 128.4, 128.2, 128.2, 128.1, 125.2, 124.8, 124.5, 124.4, 
123.5, 123.1, 122.3, 122.1, 105.1, 95.8, 72.8, 38.3. HRMS (ESI+): m/z calc’d for C27H19N2O8
+
: 
499.1136.  Found: 499.1139. 
(5R,7R,9S)-7,9-bis(3-(trifluoromethyl)phenyl)-1,6,8-trioxaspiro[4.5]decan-2-one (1.48b). 
To an argon degassed solution of 1.44b (46.9 mg, 0.105 mmol) in MeOH (0.09 M, 1.2 ml) was 
added palladium on carbon (11.2 mg, 0.105 mmol, 1 equiv.). The reaction mixture was equipped 
with a balloon of H2(g), stirred for 2 h at room temperature, and placed through a pad of Celite
®
. 
The reaction mixture was then purified by column chromatography (Silica (10 g), 2% 
EtOAc/hexanes to 25% EtOAc/hexanes gradient over 22 column volumes), giving 1.48b as a 
colorless oil (21.6 mg, 46% yield). Rf = 0.31 in 20% EtOAc in hexanes. IR (thin film, KBr): 
3075 (w), 2956 (w), 2927 (w), 2854 (w), 1790 (s), 1379 (w), 1329 (s), 1209 (s), 1166 (s), 1124 




H NMR (400 MHz, CDCl3): 
δ 7.81 (s, 1H), 7.76 – 7.49 (m, 7H), 6.22 (s, 1H), 5.36 (t, J = 7.2 Hz, 1H), 2.96 – 2.83 (m, 1H), 
2.63 (dd, J = 17.0, 8.7 Hz, 1H), 2.52 – 2.44 (m, 1H), 2.31 – 2.15 (m, 3H). 
13
C NMR (100 MHz, 
CDCl3): δ 175.5 (s), 141.1 (s), 138.0 (s), 132.0 – 130.4 (m), 130.1 (s), 129.4 (s), 129.3 (s), 129.1 
(s), 126.4 (d, J = 3.7 Hz), 125.5 (s), 125.3 (d, J = 3.8 Hz), 123.7 – 123.4 (m), 122.7                   
(d, J = 4.0 Hz), 106.3 (s), 96.1 (s), 75.2 (s), 40.9 (s), 34.6 (s), 27.7 (s). HRMS (ESI+): m/z calc’d 
for C21H16F6O4Na
+
: 469.0845.  Found: 469.0853. 
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Synthesis of 3-Methoxy-8-oxabicyclo[3.2.1]octenes: 
6-isobutyryl-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (1.66a). Triflate salt 
1.64a (258.3 mg, 0.890 mmol), N,N-diisopropylaniline (433 μL, 2.23 mmol, 2.5 equiv.),           
4-methylpent-1-yn-3-one (427.6 mg, 4.45 mmol, 5 equiv.), and CDCl3 (0.15 M, 6 mL) were 
placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL), and the reaction 
mixture was subjected to microwave irradiation at 100 °C for 45 min. The reaction mixture was 
then immediately purified by column chromatography (silica (10 g), 2% EtOAc/hexane to 35% 
EtOAc/hexane gradient over 48 column volumes), giving 1.66a as a yellow oil (148.1 mg, 70% 
yield). Rf = 0.34 in 20% EtOAc in hexanes. IR (thin film, KBr): 3082 (w), 2974 (m), 2936 (w), 
1713 (s), 1671 (s), 1610 (s), 1459 (w), 1383 (m), 1343 (m), 1291 (m), 1213 (m), 1180 (m), 1128 




H NMR (400 MHz, CDCl3): δ 6.93 (d, J = 2.2 Hz, 1H), 
6.06 (s, 1H), 4.98 (d, J = 2.4 Hz, 1H), 3.46 (s, 3H), 3.02 (sept, J = 6.9 Hz, 1H), 1.61 (s, 3H), 1.07 
(d, J = 7.1 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H). 
13
C NMR (100 MHz, CDCl3): δ 201.3, 188.8, 
155.5, 144.9, 136.7, 119.8, 86.2, 85.9, 54.6, 37.9, 21.0, 19.5, 17.6. HRMS (ESI+): m/z calc’d for 
C13H17O4
+
: 237.1121. Found: 237.1124. 
6-(cyclohexanecarbonyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one 
(1.66b). Triflate salt 1.64a (94 mg, 0.324 mmol), N,N-diisopropylaniline (75.7 μL, 0.389 mmol, 
1.2 equiv.), 1-cyclohexylprop-2-yn-1-one (220.5 mg, 1.62 mmol, 5 equiv.), and CHCl3 (0.16 M, 
2 mL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL), and the 
reaction mixture was subjected to microwave irradiation at 100 °C for 45 min. The reaction 
mixture was then immediately purified by column chromatography (silica gel, 18 cm x 1.8 cm, 
solvent gradient: 5% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100 mL); 20% 
EtOAc in hexanes (200 mL); 30% EtOAc in hexanes (100 mL)), giving 1.66b as a yellow oil 
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(78.2 mg, 87% yield). Rf = 0.24 in 15% EtOAc in hexanes. IR (thin film, KBr): 3063 (w), 2928 
(m), 2853 (m), 1709 (s), 1667 (s), 1609 (s), 1450 (m), 1444 (m), 1337 (m), 1263 (m), 1179 (m), 




H NMR (400 MHz, CDCl3): δ 6.91           
(d, J = 2.5 Hz, 1H), 6.05 (s, 1H), 4.97 (d, J = 2.6 Hz, 1H), 3.45 (s, 3H), 2.72 (ddd, J = 11.2, 7.2, 
3.4 Hz, 1H), 1.85 – 1.61 (m, 5H), 1.59 (s, 3H), 1.47 – 1.06 (m, 5H). 
13
C NMR (100 MHz, 
CDCl3): δ 200.7, 188.8, 155.5, 144.9, 136.5, 119.9, 86.2, 85.9, 54.6, 48.0, 29.9, 27.7, 25.8, 25.7, 
25.1, 21.0. HRMS (ESI+): m/z calc’d for C16H21O4
+
: 277.1434. Found: 277.1439. 
6-(2-cyclohexylacetyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (1.66c). 
Triflate salt 1.64a (100 mg, 0.345 mmol), N,N-diisopropylaniline (80.6 μL, 0.414 mmol,         
1.2 equiv.), 1-cyclohexylbut-3-yn-2-one (258 mg, 1.72 mmol, 5 equiv.), and CH2Cl2 (0.16 M,  
2.2 mL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL), and 
the reaction mixture was subjected to microwave irradiation at 100 °C for 35 min. The reaction 
mixture was then immediately purified by column chromatography (silica (10 g), 2% 
EtOAc/hexane to 35% EtOAc/hexane gradient over 46 column volumes), giving 1.66c as a 
yellow oil (68.1 mg, 67% yield). Rf = 0.20 in 15% EtOAc in hexanes. IR (thin film, KBr): 3081 
(w), 2924 (s), 2851 (s), 1713 (s), 1668 (s), 1609 (s), 1449 (m), 1342 (m), 1303 (w), 1190 (m), 




H NMR (400 MHz, CDCl3): δ 
6.96 (d, J = 2.3 Hz, 1H), 6.07 (s, 1H), 5.01 (d, J = 2.4 Hz, 1H), 3.50 (s, 3H), 2.55 (dd, J = 15.3, 
6.5 Hz, 1H), 2.44 (dd, J = 15.3, 7.3 Hz, 1H), 1.88 – 1.75 (m, 1H), 1.67 (s, 3H), 1.72 – 1.54      
(m, 5H), 1.30 – 1.02 (m, 3H), 1.00 – 0.80 (m, 2H). 
13
C NMR (100 MHz, CDCl3): δ 197.2, 
189.0, 156.8, 145.1, 137.7, 119.8, 86.2, 85.9, 54.7, 47.9, 34.7, 33.4, 33.2, 26.2, 26.1, 26.1, 21.3. 
HRMS (ESI+): m/z calc’d for for C17H23O4
+
: 291.1591. Found: 291.1593. 
29  
6-([1,1'-Biphenyl]-4-carbonyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one 
(1.66d). Triflate salt 1.64a (100 mg, 0.345 mmol), N,N-diisopropylaniline (81 μL, 0.414 mmol, 
1.2 equiv.), 1-([1,1'-biphenyl]-4-yl)prop-2-yn-1-one (712 mg, 3.45 mmol, 10 equiv.), and CH2Cl2 
(0.07 M, 5 mL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,           
10-20 mL), and the reaction mixture was subjected to microwave irradiation at 100 °C for 1 h. 
The reaction mixture was then immediately concentrated and purified by column 
chromatography (silica (10 g), 0% EtOAc/hexane to 35% EtOAc/hexane gradient over              
20 column volumes), giving 1.66d as an orange solid (92.8 mg, 77% yield). MP = 156-159 °C. 
Rf = 0.22 in 20% EtOAc in hexanes. IR (thin film, KBr): 3063 (w), 2979 (w), 2935 (w), 2837 
(w), 1711 (s), 1641 (m), 1603 (s), 1449 (w), 1323 (m),  1228 (w), 1127 (m), 1043 (w), 989 (w), 




H NMR (400 MHz, CDCl3): δ 7.93 (d, J = 8.3 Hz, 2H), 7.71 
(d, J = 8.3 Hz, 2H), 7.65 – 7.61 (m, 2H), 7.51 – 7.39 (m, 3H), 6.83 (d, J = 2.4 Hz, 1H), 6.30      
(s, 1H), 5.20 (d, J = 2.5 Hz, 1H), 3.60 (s, 3H), 1.77 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 
190.2, 188.5, 155.1, 146.5, 145.1, 139.6, 138.6, 135.5, 129.7, 129.1, 128.5, 127.4, 127.3, 120.4, 
87.2, 86.8, 54.8, 20.9. HRMS (ESI+): m/z calc’d for C22H19O4
+
: 347.1278. Found: 347.1280. 
Synthesis of α-Hydroxytropolones: 
2,7-dihydroxy-4-isobutyryl-5-methylcyclohepta-2,4,6-trien-1-one (1.68a). To a solution of 
bicycle 1.66a (31.8 mg, 0.127 mmol) in CH2Cl2 (1.5 M, 86.7 μL) was added triflic acid (45.0 μL, 
0.507 mmol, 4 equiv.). The reaction mixture was allowed to stir for 30 min, after which time it 
was quenched with sodium acetate (98 mg, 1.20 mmol, 10 equiv.), stirred for 20 min, and 
concentrated under reduced pressure. The crude mixture was then dissolved in 25% HBr in 
acetic acid (4 mL), and heated to 90 ºC for 4 h.The reaction mixture was cooled to room 
temperature, quenched with phosphate buffer (pH 7, 10 mL), and diluted with CH2Cl2 (5 mL). 
30  
The organic layer was washed with phosphate buffer (pH 7, 3 x 10 mL), dried over Na2SO4, 
filtered, and concentrated to give 1.68a as a brown oil (21.7 mg, 77% yield). IR (thin film, 
KBr): 3261 (br), 2971 (w), 2933 (w), 2873 (w), 1701 (m), 1538 (m), 1465 (m), 1397 (m), 1384 




H NMR        
(400 MHz, CDCl3): δ 7.47 (s, 1H), 7.28 (s, 1H), 3.14 (sept, J = 6.9 Hz, 1H), 2.38 (s, 1H), 1.21 
(d, J = 6.9 Hz, 1H). 
13
C NMR (50 MHz, CDCl3): δ 210.3, 168.2, 158.8, 157.3, 141.5, 137.8, 
124.8, 118.1, 40.7, 24.6, 18.2. HRMS (ESI+): m/z calc’d for C12H15O4
+
: 223.0965. Found: 
223.0965. 
4-(cyclohexanecarbonyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.68b). To a 
solution of bicycle 1.66b (35.1 mg, 0.121 mmol) in CH2Cl2 (95.3 μL) was added triflic acid 
(43.0 μL, 0.486 mmol, 4 equiv.). The reaction mixture was allowed to stir for 30 min, after 
which time it was quenched with sodium acetate (99 mg, 1.21 mmol, 10 equiv.), stirred for       
20 min, and concentrated under reduced pressure. The crude mixture was then dissolved in 25% 
HBr in acetic acid (2 mL) and heated to 90 ºC for 4 h. The reaction mixture was cooled to room 
temperature, quenched with phosphate buffer (pH 7, 10 mL), and diluted with CH2Cl2 (5 mL). 
The organic layer was washed with phosphate buffer (pH 7, 3 x 10 mL), dried over Na2SO4, 
filtered, and concentrated to give 1.68b as a black oil (26.6 mg, 84% yield). IR (thin film, KBr): 
3262 (br), 2930 (s), 2854 (s), 1698 (m), 1538 (s), 1449 (s), 1395 (m), 1281 (s), 1233 (s), 1193 




H NMR (400 MHz, 
CDCl3): δ 7.46 (s, 1H), 7.28 (s, 1H), 2.89 – 2.76 (m, 1H), 2.37 (s, 3H), 1.98 – 1.65 (m, 5H),  
1.51 – 1.16 (m, 5H). 
13
C NMR (100 MHz, CDCl3): δ 209.6, 168.2, 158.7, 157.2, 141.7, 137.8, 





4-(2-cyclohexylacetyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.68c). To a 
solution of bicycle 1.66c (31.2 mg, 0.103 mmol) in CH2Cl2 (0.11 M, 900 μL) was added triflic 
acid (37.0 μL, 0.413 mmol, 4 equiv.). The reaction mixture was allowed to stir for 30 min, after 
which time it was quenched with sodium acetate (85 mg, 1.03 mmol, 10 equiv.), stirred for       
20 min, and concentrated under reduced pressure. The crude mixture was then dissolved in 25% 
HBr in acetic acid (2 mL) and heated to 90 ºC for 4 h. The reaction mixture was cooled to room 
temperature, quenched with phosphate buffer (pH 7, 10 mL), and diluted with CH2Cl2 (5 mL). 
The organic layer was washed with phosphate buffer (pH 7, 3 x 10 mL), dried over Na2SO4, 
filtered, and concentrated to give 1.68c as a brown oil (23.3 mg, 82% yield). IR (thin film, 
KBr): 3255 (br), 2924 (s), 2852 (m), 1704 (m), 1538 (s), 1448 (m), 1397 (m), 1351 (m), 1280 




H NMR           
(400 MHz, CDCl3): δ 7.46 (s, 1H), 7.27 (s, 1H), 2.67 (d, J = 6.7 Hz, 2H), 2.40 (s, 3H),          
2.06 – 1.94 (m, 1H), 1.84 – 1.61 (m, 5H), 1.38 – 0.93 (m, 5H). 
13
C NMR (50 MHz, CDCl3): δ 
206.1, 168.1, 158.8, 157.4, 142.3, 137.4, 125.0, 118.1, 50.9, 33.6, 33.4, 26.3, 26.2, 24.4. HRMS 
(ESI+): m/z calc’d for C16H21O4
+
: 277.1434. Found: 277.1441. 
4-([1,1'-biphenyl]-4-carbonyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (1.68d). 
To a solution of bicycle 1.66d (46.4 mg, 0.134 mmol) in CH2Cl2 (0.09 M, 1.5 mL) was added 
trifluoromethanesulfonic acid (47.3 μL, 0.536 mmol, 4 equiv.). The reaction mixture was 
allowed to stir for 30 min, after which time it was quenched with sodium acetate (110 mg,     
1.34 mmol, 10 equiv.), stirred for 20 min, and concentrated under reduced pressure. The crude 
mixture was then dissolved in 25% HBr in acetic acid (2 mL), and heated to 90 ºC for 4 h. The 
reaction mixture was cooled to room temperature, quenched with phosphate buffer (pH 7,         
10 mL), and diluted with CH2Cl2 (5 mL). The organic layer was washed phosphate buffer (pH 7, 
32  
3 x 10 mL), dried over Na2SO4, filtered, and concentrated to give 1.68d as a brown oil (26.2 mg, 
59% yield). IR (thin film, KBr): 3262 (br), 3060 (w), 2961 (w), 1669 (s), 1601 (s), 1534 (s), 





H NMR (400 MHz, CDCl3): δ 7.88 (d, J = 8.2 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.63   
(d, J = 7.4 Hz, 2H), 7.54 (s, 1H), 7.52 – 7.39 (m, 3H), 7.36 (s, 1H), 2.36 (s, 3H). 
13
C NMR    
(100 MHz, CDCl3): δ 196.8, 168.5, 158.8, 157.1, 147.3, 140.0, 139.7, 138.2, 134.4, 130.9, 
129.2, 128.8, 127.8, 127.5, 124.5, 119.0, 24.7. HRMS (ESI+): m/z calc’d for C21H17O4
+
: 
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The Discovery and Development of a Three-Component Oxidopyrylium 
Cycloaddition  
2.1. Analyzing the Oxidopyrylium Cycloaddition/Ring-Opening Route to αHTs 
2.1.1. Synthetic Method Limitations 
 As reviewed in the previous chapter, our laboratory has reported an oxidopyrylium 
cycloaddition/acid-mediated ring-opening approach to gain access to polysubstituted αHTs 
(Scheme 2.1).
49
 This strategy has allowed us to construct a sizable library of over 60 derivatives 
that have been dedicated to medicinal chemistry studies for several therapeutically significant 
targets.
52-56
 Nevertheless, the synthetic method is not without limitation in regards to SAR and 
chemical probe development. Specifically, the strongly acidic demethylation conditions required 
for conversion of 2.5 to 2.6 prevent the introduction of a wide range of pharmacologically 
relevant functional groups (e.g. many amides, esters, amines, etc.)
64
 and activity-based probes 
and linkers (e.g. diazarines and pegylated biotin)
65
 to the αHT scaffold (Figure 2.1). 
Demethylation generally necessitates harsh reagents and procedures that are not functional group 
56  
tolerant, including boron tribromide (BBr3) and HBr/AcOH or LiCl/DMSO at high 
temperatures.
66
 Thus, in order to address the restrictions on αHT design, the final step of our 
route must be bypassed.  
2.1.2. 3-Hydroxy-4-Pyrone-Based Oxidopyrylium Cycloadditions and Their Origins 
 To carry out this task, we must first understand the importance of the methoxy 
functionality to the overall αHT synthesis. The incorporation of the methyl ether that requires 
deprotection at the end of Scheme 2.1 occurs during the formation of triflate salt 2.2. The 
methoxy group enables the following intermolecular [5 + 2] cycloaddition reaction between 2.2 
and alkynes (2.3) in the presence of base to produce the oxabicyclic intermediates (2.4). Also 
classified as a 3-hydroxy-4-pyrone-based oxidopyrylium cycloaddition, this process 





Historically, various methods have been employed using kojic acid derivatives to create 
the essential zwitterionic intermediate in situ (Scheme 2.2). Most synthetic strategies leverage 
the tautomerization or rearrangement of 3-hydroxy-4-pyrones to oxidopyrylium ylides            
(2.12 → 2.13, Path A).
67
 However, higher temperatures are necessary to initiate the reaction, 
which exclude many thermally unstable alkenyl and alkynyl substrates.
68
 In addition, 
oxidopyrylium cycloadditions performed through group transfer are only effective for 
intramolecular processes due to the transience of the active ylide.
67,68
 
To circumvent the high temperature rearrangement, Wender and co-workers developed 
an alternative and milder approach whereby the ylide is created through simple activation of a 
methyl triflate-derived oxidopyrylium salt (2.15 → 2.16, Path B).
69
 The triflate salt or 
‘pre-ylide’ is initially synthesized by executing an O-4 alkylation on 3-hydroxy-4-pyrones with 
methyl triflate (MeOTf). The resulting salt then engages in low temperature [5 + 2] 
cycloadditions when exposed to a non-nucelophilic base or a fluoride source, depending on the 
58  
nature of the R group at O-3. With this method in hand, the Wender group not only demonstrated 
intramolecular reactions
69a
 but reported the intermolecular construction of cycloadducts with 
both alkenes and alkynes (Scheme 2.3).
69b
  
 In our synthetic route to αHTs, we utilize a modified version of the oxidopyrylium 
cycloaddition developed by Wender and co-workers.
49a
 A key characteristic of oxidopyrylium 
ylides is their capacity to dimerize upon formation (Scheme 2.4A).
70
 Believing the dimerization 
to be detrimental to the overall productivity of the intermolecular oxidopyrylium cycloaddition, 
the Wender group optimized against this process by using lower temperatures and a weaker base 
(i.e. N,N-dimethylaniline, Scheme 2.3).
69b
 However, the work conducted in our laboratory by 
Dr. Christine Meck illustrated that the dimerization is reversible, as a cycloaddition between 
dimer 2.24a and dimethyl acetylenedicarboxylate (DMAD) occurs when heated (Scheme 
2.4B).
49a
 In addition, our laboratory discovered that ylide 2.23a demethylates in the presence of 
N,N-dimethylaniline at higher temperatures, effectively destroying the reaction (Scheme 2.4C). 
The demethylation was suppressed with the use of a bulkier base, N,N-diisopropylaniline, 
59  
permitting an efficient intermolecular oxidopyrylium cycloaddition with a variety of alkynes 
(Scheme 2.5 for select examples).  
In summary, the harsh demethylation conditions required at the final stage of our αHT 
synthesis emerge as a result of the stipulations set by the oxidopyrylium cycloaddition. The O-4 
methylation of 3-hydroxy-4-pyrone derivatives to oxidopyrylium triflate salts allows for facile 
and effective intra- and intermolecular [5 + 2] cycloadditions versus reaction variants that rely on 
60  
high temperature group transfers and tautomerization. Thus, we shifted our efforts towards 
adjusting the cycloaddition phase of Scheme 2.1 in order to remove the methoxy functionality. 
2.1.3. Attempts at Synthesizing Alternative Oxidopyrylium Triflate Salts  
 As detailed earlier, triflate salt 2.2a is very easily generated by methylating allomaltol 
(2.18) with MeOTf.
49a,69b
 The process permits a gram-scale synthesis of 2.2a, which is both 
storable and bench-stable. In principle, 3-hydroxy-4-pyrones should react with alternative alkyl 
triflates to produce novel oxidopyrylium salts. Nevertheless, attempts performed by our 
laboratory to synthesize other triflate-derived species, including benzyl and trifluoroethyl triflate 
analogs, have been unsuccessful. Therefore, a different strategy is needed to bypass the 
formation of α-methoxyenone-containing oxabicycles.    
2.2. The Three-Component Oxidopyrylium [5 + 2] Cycloaddition 
2.2.1. Serendipitous Discovery and Initial Optimization with Triflate Salt/Base 
Due to a serendipitous discovery made by Dr. Christine Meck, our laboratory was able to 
develop a procedure to overcome the limitation of exclusively synthesizing α-methoxyenone-
derived oxabicyclic intermediates.
71
 Specifically, when ylide 2.23 is treated with various 
alcohols prior to the oxidopyrylium cycloaddition, a three-component process transpires, 
resulting in the generation of new oxabicyclic products (2.27, Scheme 2.6). The original 
observation was made while conducting slower oxidopyrylium cycloaddition reactions with  
61  
 










































































[a] Reaction temperatures and times correspond to the first step. [b] Yields were calculated on the basis 
of combined 2.4f and 2.27a, and ratios were determined by 
1
H NMR integration. [c] Heated with 
microwave irradiation. [d] Conventional heating throughout reaction. 
 
ethanol-stabilized chloroform (Table 2.1, Entry 1). Chloroform (CHCl3) with ethanol (EtOH) 
stabilizer typically contains 1% alcohol concentration, which corresponds to 0.33 equivalents 
under our studied conditions. Following an oxidopyrylium cycloaddition between triflate salt 
2.2a and phenylacetylene in the presence of base, approximately 15% of the overall yield is 
attributed to the α-ethoxyenone compound 2.27a. 
Moving forward with this finding, we ventured to optimize the process towards a higher 
output of 2.27a. Our results revealed that an increase in EtOH concentrations led to more 
incorporated product, while having no influence on total bicyclic yields (Entries 2-3). 
Prolonging the oxidopyrylium cycloaddition did not improve 2.27a production, and resubjecting 
bicycle 2.4f to the reaction conditions with EtOH gave no noticeable incorporation. On the other 
62  
hand, when the oxidopyrylium ylide was reacted with alcohol for a period of time prior to alkyne 
addition, 2.27a was provided in larger quantities (Entries 4-8). However, upon exposing the 
ylide and alcohol to higher temperatures and longer reaction times, observed yields decreased 
markedly (Entries 9-10). Lastly, since a multi-hour process in a microwave reactor is 
impractical, the three-component cycloaddition was investigated with conventional heating. 
Similar yields were obtained between experiments with different heating methods, allowing for 
the study of a wider range incorporation times (Entries 7 vs. 11). 
After deeming it viable to obtain yields around 50% for 2.27a with a three-component 
reaction, we attempted to generate a series of novel oxabicycles by incorporating alternative 
alcohols (Table 2.2). During the substrate scope, we found that each alcohol required new 
optimization conditions and demonstrated varying levels of efficiency. For example, the more 
sterically demanding alcohols, such as isopropanol and neopentanol, produced 2.27m and 2.27k 
in lower overall yields and demanded much longer reaction times (Entries 4-9). Alcohols with 
even greater steric demand (e.g. t-butanol and trimethylsilanol) displayed no observable 
incorporation (not shown). Benzyl and allyl alcohols provided lower yields of 2.27f and 2.27n at 
60 ºC for 2 h, demanding shorter intervals and lower temperatures for optimization (Entries 10-
15). Lastly, attempts at using electron rich substituents, such as p-methoxybenzyl (PMB) alcohol, 
failed to supply incorporated species, and instead led to the formation of allomaltol (not shown).  
Overall, though reasonably effective for ethanol incorporation, the initial optimization 
conditions involving triflate salt 2.2a and base were not very versatile. We speculated that the 
reduction in efficiency for other alcohols involved decomposition pathways mediated by the 
conjugate acid that forms after deprotonation of 2.2a. Thus, our focus shifted toward conducting 
























































































[a] Reaction temperatures and times are for the first step of process prior to addition of alkyne. [b] Yield 
calculated from combined isolated 2.4f and 2.27. [c] Average of 2 separate runs. 
 
2.2.2. Mechanistic Hypothesis and Re-Optimization with Oxidopyrylium Dimer 
Considering the preliminary results, our proposed mechanistic hypothesis for the alcohol 
incorporation involves a nucleophilic aromatic substitution on ylide 2.23 (Scheme 2.7). Though 
2.23 rapidly dimerizes to 2.24 and cannot be detected in solution, the transformation is presumed 
to be reversible based on previous reports from our laboratory.
49a
 The interconversion ultimately 
allows the alcohol to interact with 2.23, generating new ylide species (2.26) that further 
undergoes cycloaddition. Alcohol exchange directly with the dimer is improbable due to the 
requirement for an SN1-type reaction on a bridgehead carbon and/or the replacement of an 
64  
α-alkoxy group on an enone. Nonetheless, the incorporation mechanism could reasonably entail 
an unknown intermediate between the ylide and dimer. Studies are currently being performed in 
order obtain a better mechanistic understanding of the three-component reaction. 
In order to increase the efficiency of the synthetic method, we leveraged the reversible 
dimerization.
71
 The purified dimer 2.24a was readily prepared in high yields by adding 
triethylamine to triflate salt 2.2a, then performing an aqueous ammonium chloride wash. We 
surmised that eliminating residual base and stoichiometric conjugate acid emerging from 
deprotonation of 2.2a would permit longer incorporation times and limit decomposition. This 
assumption was verified as experiments conducted with oxidopyrylium dimer provided greater 
overall yields and tolerated prolonged exposure to heating conditions in comparison to the 
triflate salt/base combination (Table 2.3). The optimal reaction time for this process was 12 
hours, as anything beyond that led to comparable amounts of 2.27b. In addition, lower overall 
yields were observed with the 18 and 24 hour time points due to the formation of less 2.4h.   
65  
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[a] Equivalents are calculated on the basis of monomeric ylide for consistency. [b] Time for first step, with 
conventional heating. [c] Isolated yields following silica gel chromatography. [d] Product 2.4h was isolated 
along with benzyl alcohol, and yields were approximated on the basis of the 
1
H NMR integration ratio of 
signature peaks of 2.4h and benzyl alcohol. 
 
With these new reaction conditions in hand, we decided to employ alternative alkynes 
and alcohols to the system (Table 2.4). Benzyl-containing oxabicyclic intermediates with a 
variety of substituents were generated in 40-65% yield (2.27b-f). Benzyl alcohols with distinct 
electronic properties were also used with comparable results (2.27g-h), as electronically poor 




methyl ether groups was implemented without any competitive transetherification (2.27i). 
Primary alcohols with adjacent sterics (2.27j-k) or base-sensitive functionality (2.27l) were 
successfully incorporated. However, steric limitations apply, with secondary alcohols 
necessitating longer reaction times and producing lower yields (2.27m), and tertiary alcohols 
showing no product formation. Allyl alcohol again provided diminished yields, which may be 
due to competing Claisen-rearrangement-type decomposition pathways (2.27n). In a majority of 
cases, an excess amount of alkyne (20 equiv.) was used to maximize product output. 
Nonetheless, for more costly reagents, as represented by 1,4-diethynylbenzene, such liberal 
usage can be prohibitive. For these situations, decreased quantities of alkyne (10 equiv.) can be 
employed with comparable yields (2.27o), and the alkyne can be recovered and recycled (i.e. 
80% recovery at a net consumption of 2 equiv.).  
 In summary, we successfully re-optimized the three-component oxidopyrylium 
cycloaddtion by utilizing the purified dimer 2.24a and removing the base from the system. This 
protocol granted access to a series of novel α-alkoxyenone-containing oxabicycles through the 
incorporation of various alcohols and alkynes, which could not be achieved with the triflate 
salt/base combination (Table 2.4). Many of these compounds possess acid- or base-sensitive 
protecting groups, such as benzyl and cyanoethyl functionalities respectively, that require much 
milder conditions to cleave in comparison to methyl ethers.
66
 Thus, our next step was to apply 
the newly developed synthetic method towards αHT generation.  
2.2.3. Utility of Three-Component Reaction in αHT Synthesis 
Considering benzyl ethers are widely used in protecting group chemistry and can be 
removed more easily than methyl appendages with much weaker acids,
66
 our studies began with 




discovered that treatment of 2.27f with methane sulfonic acid leads directly to the αHT 2.6a, 
despite the presence of benzyl methanesulfonate impurity (Scheme 2.8, Method A). In order to 





 The obtained yields from the resin reaction were lower, but the product was 
much cleaner (Scheme 2.8, Method B). It must be noted that with the latter method, an aqueous 
wash is necessary to dissociate the αHT from the resin, most likely due to hydrogen bonding 
between the troponoid system and solid-bound sulfonic acids. While the overall mechanism for 
the deprotections is unknown, shorter reaction times lead to observable amounts of 
benzyloxytropolones along with 2.6a, suggesting that ring opening occurs prior to 
debenzylation.
71
 Overall, these promising results demonstrated that the three-component 
oxidopyrylium cycloaddition can be leveraged to synthesize αHTs with much milder conditions 
than previously outlined. 
2.3. Conclusion 
Our group has discovered and developed a new three-component 3-hydroxy-4-pyrone-
based oxidopyrylium cycloaddition that generates novel oxabicyclic compounds.
71
 The data 
69  
presented above illustrates the potential utility of the synthetic method towards αHT assembly, as 
a wider range of milder deprotection conditions can be used to bypass harsher demethylation 
requirements. The remainder of this thesis will describe further applications of the three-
component reaction, specifically detailing the solid-phase and fluorous supported synthesis of 
αHTs. 
2.4. Experimental and Supporting Information 
General Information: All starting materials and reagents were purchased from commercially 
available sources and used without further purification, with exception of CH2Cl2, which was 




H NMR shifts are measured using 
the solvent residual peak as the internal standard (CHCl3 δ 7.26), and reported as follows: 
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet 
of doublet, q = quartet, m = multiplet), coupling constant (Hz), integration. 
13
C NMR shifts are 
measured using the solvent residual peak as the internal standard (CDCl3 δ 77.16), and reported 
as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong (s), 
medium (m), and weak (w). Mass spectra were recorded on a spectrometer by electrospray 
ionization (ESI) technique and time-of-flight (TOF) mass analyzer. Microwave reactions were 
performed via the Biotage
®
 Intiator (External IR Temperature Sensor). Where noted, reaction 
products were purified via silica gel chromatography using a Biotage
®
 Isolera Prime, with 
Biotage
® 
SNAP 10 g cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane.  




10,12-dione (2.24a). To a solution of triflate salt 2.2a (5 g, 17.2 mmol) in CH2Cl2 (43 ml) was 
added triethylamine (2.89 mL, 20.7 mmol, 1.2 equiv.). After it was stirred for 10 min at room 
70  
temperature, the reaction mixture was washed with aqueous NH4Cl (5 x 50 mL). The organic 
layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to yield 2.24a as 
a pale yellow solid (2.21 g, 92% yield), demonstrating 
1





H NMR (400 MHz, CDCl3): δ 5.89 (s, 1H), 4.74 (d, J = 2.7 Hz, 1H), 4.69     




4,8-diene-10,12-dione (2.24b). To a solution of 5-hydroxy-4-methoxy-2-(methoxymethyl)-
pyrylium trifluoromethanesulfonate (1.64 g, 5.12 mmol) in CH2Cl2 (13 ml) was added 
triethylamine (857 μL, 6.15 mmol, 1.2 equiv.). After it was stirred for 10 min at room 
temperature, the reaction mixture was washed with aqueous NH4Cl (5 x 20 mL). The organic 
layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to yield 2.24b as 
a brown solid (683.4 mg, 78% yield). Melting Point (MP) = 140-143 ºC. Rf = 0.25 in 50% 
EtOAc in hexanes. IR (thin film, KBr): 3074 (w), 2938 (m), 2839 (m), 1748 (s) 1705 (s), 1669 





H NMR (400 MHz, CDCl3): δ 6.00 (s, 1H), 5.00 (s, 1H), 4.91 (d, J = 2.7 Hz, 1H), 
4.54 (d, J = 2.7 Hz, 1H), 4.03 (d, J = 13.5 Hz, 1H), 3.96 (d, J = 13.6 Hz, 1H), 3.88                    
(d, J = 10.4 Hz, 1H), 3.67 (d, J = 11.1 Hz, 1H), 3.66 (s, 3H), 3.47 (s, 3H), 3.43 (s, 3H), 3.43      
(s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 197.4, 185.1, 157.2, 151.2, 115.7, 95.7, 87.3, 86.6, 
85.2, 82.1, 73.5, 70.6, 59.9, 58.7, 55.4, 54.4. HRMS (ESI+): m/z calc’d for C16H21O8
+
: 
341.1231. Found: 341.1233. 
Procedure for Alcohol Incorporation/Cycloaddition Sequence: 
3-Ethoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27a). Representative 
Procedure for Synthesis of 2.27a. Triflate salt 2.2a (50 mg, 0.172 mmol), N,N-diisopropyl 
71  
aniline (41 μL, 0.208 mmol, 1.2 equiv.), and CDCl3 (0.5 M, 344 μL) were placed in a sealed tube 
reactor (Biotage
®
 microwave reaction vial, 0.5-2 mL) and stirred until no solid was observed. 
Ethanol (50 μL, 0.860 mmol, 5 equiv.) was then added, and the reaction mixture was heated to 
60 ºC in silicone oil bath for 2 h. After the reaction mixture was cooled to room temperature, 
phenyl acetylene (378 µL, 3.44 mmol, 20 equiv.) was added and the sealed tube was heated to 
100 ºC for 30 min. The reaction mixture was then immediately purified by column 
chromatography (silica gel, 6 in. height of silica gel, 18 cm x 1.8 cm, solvent gradient: hexanes 
(50 mL); 5% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in 
hexanes (150 mL)). Product fractions were concentrated to give 2.27a as a yellowish oil (17 mg, 
38% yield) and 2.4f as a yellow solid (8 mg, 19% yield). The 
1
H NMR for 2.4f was consistent 
with previously reported data.
49a
 Characterization Data for 2.27a. Rf = 0.21 in 15% EtOAc in 
hexanes. IR (thin film, KBr): 3057 (w), 2981 (m), 2936 (w), 1713 (s), 1603 (s), 1493 (m), 1446 




H NMR (400 MHz, CDCl3): δ 7.41 – 7.30 (m, 3H), 7.30 – 7.25 (m, 2H), 6.27 (d, J = 2.5 Hz, 
1H), 6.18 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.85 – 3.67 (m, 2H), 1.66 (s, 3H), 1.36 (t, J  = 7.0 Hz, 
3H). 
13
C NMR (50 MHz, CDCl3): δ 190.2, 158.8, 145.2, 133.2, 128.82, 128.77, 126.1, 123.2, 
119.7, 86.5, 86.0, 63.3, 22.2, 14.3. HRMS (ESI+):
 
m/z calc’d for C16H17O3
+
: 257.1172. Found: 
257.1173. 
tert-Butyl 3-(benzyloxy)-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate  
(2.27b). Representative Procedure Employing Method A. Triflate salt 1 (50 mg, 0.172 mmol), 
N,N-diisopropyl aniline (41 μL, 0.208 mmol, 1.2 equiv.), and CH2Cl2 (0.5 M, 344 μL) were 
placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 0.5-2 mL) and stirred until no 
solid was observed. Benzyl alcohol (89 μL, 0.860 mmol, 5 equiv.) was then added, and the 
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reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. After the reaction mixture was 
cooled to room temperature, tert-butyl propiolate (472 µL, 3.44 mmol, 20 equiv.) was added to 
the sealed tube, and the reaction mixture was subjected to microwave irradiation at 100 ºC for  
15 min. The reaction mixture was then immediately purified by column chromatography (silica 
(10 g), 0% EtOAc/hexane to 10% EtOAc/hexane gradient over 30 column volumes), yielding 
2.27b as a white solid (21.6 mg, 37% yield) and 2.4h as a white solid (8.3 mg, 18%). 
Representative Procedure Employing Method B. Dimer 2.24a (24 mg, 0.0860 mmol), benzyl 
alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2 (0.25 M, 344 μL) were placed in a sealed 
tube reactor (Biotage
®
 microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated 
to 60 ºC in silicone oil bath for 12 h. tert-Butyl propiolate (472 µL, 3.44 mmol, 40 equiv.) was 
added to the sealed tube, and the reaction mixture was subjected to microwave irradiation at   
100 ºC for 15 min. The reaction mixture was then immediately purified by column 
chromatography (silica (10 g), 0% EtOAc/hexane to 10% EtOAc/hexane gradient over              
25 column volumes), yielding 2.27b as a white solid (30.8 mg, 52% yield) and 2.4h as a white 
solid (10.8 mg, 24%). Characterization Data for 2.27b. MP = 99-102 ºC. Rf = 0.22 in 10% 
EtOAc in hexanes. IR (thin film, KBr): 3065 (w), 3034 (w), 2978 (w), 2936 (w), 1706 (s), 1614 





H NMR (400 MHz, CDCl3): δ 7.38–7.27 (m, 5H), 6.98 (d, J = 2.5 Hz, 1H), 6.13     
(s, 1H), 4.99 (d, J = 2.5 Hz, 1H), 4.80 (d, J = 11.9 Hz, 1H), 4.73 (d, J = 11.9 Hz, 1H), 1.72        
(s, 3H), 1.48 (s, 9H). 
13
C NMR (100 MHz, CDCl3): δ 189.0, 162.2, 151.1, 144.0, 137.8, 135.6, 
128.7, 128.3, 127.6, 121.6, 86.0, 85.5, 82.3, 69.6, 28.2, 21.5. HRMS (ESI+): m/z calc’d for 
C20H23O5
+
: 343.1540. Found: 343.1545. Characterization Data for 2.4h. MP = 82-85 ºC.          
Rf = 0.26 in 15% EtOAc in hexanes. IR (thin film, KBr): 3092 (w), 2979 (w), 2937 (w), 1708 
73  
(s), 1615 (m), 1605 (m), 1456 (w), 1369 (m), 1328 (m), 1272 (m), 1161 (m), 1128 (m), 1073 (m), 




H NMR (400 MHz, CDCl3): δ 6.96 (d, J = 2.5 Hz, 1H), 6.06 
(s, 1H), 4.97 (d, J = 2.5 Hz, 1H), 3.55 (s, 3H), 1.74 (s, 3H), 1.50 (s, 9H). 
13
C NMR (50 MHz, 
CDCl3): δ 189.2, 162.3, 151.1, 145.1, 137.6, 119.7, 85.8, 85.6, 82.4, 54.8, 28.3, 21.5. HRMS 
(ESI+): m/z calc’d for C14H19O5
+
: 267.1227. Found: 267.1229. 
Ethyl 3-(benzyloxy)-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate (2.27c). 
Dimer 2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2 
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,       
0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Ethyl 
propiolate (349 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture 
was subjected to microwave irradiation at 100 ºC for 15 min. The reaction mixture was then 
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 15% 
EtOAc/hexane gradient over 33 column volumes), giving 2.27c as a yellow oil (29.6 mg, 55%) 
and 2.4d as a yellow oil (4 mg, 10% yield). The 
1
H NMR for 2.4d was consistent with previously 
reported data.
49a
 Characterization Data for 2.27c. Rf = 0.25 in 15% EtOAc in hexanes. IR (thin 
film, KBr): 3065 (w), 2982 (w), 2937 (w), 1711 (s), 1615 (m), 1602 (m), 1455 (m), 1370 (m), 




H NMR   
(400 MHz, CDCl3): δ 7.37 – 7.27 (m, 5H), 7.09 (d, J = 2.5 Hz, 1H), 6.16 (s, 1H), 5.03             
(d, J = 2.5 Hz, 1H), 4.77 (d, J = 11.7 Hz, 1H), 4.72 (d, J = 11.7 Hz, 1H), 4.30 – 4.17 (m, 2H), 
1.75 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3): δ 188.7, 162.9, 149.6, 
144.1, 138.8, 135.4, 128.7, 128.3, 127.7, 121.4, 86.2, 85.6, 69.7, 61.3, 21.4, 14.3. HRMS 
(ESI+): m/z calc’d for C18H19O5
+
: 315.1227. Found: 315.1228. 
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6-Acetyl-3-(benzyloxy)-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27d). Dimer  
2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2    
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,       
0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for 12 h. 3-Butyne-2-one 
(269 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture was 
subjected to microwave irradiation at 100 ºC for 15 min. The reaction mixture was then 
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 25% 
EtOAc/hexane gradient over 60 column volumes), giving 2.27d as a pale yellow solid (32 mg, 
65% yield) and 2.4e as a yellow solid (5.8 mg, 16%). The 
1
H NMR for 2.4e was consistent with 
previously reported data.
49a
 Characterization Data for 2.27d. MP = 84-87 ºC. Rf = 0.32 in 25% 
EtOAc in hexanes. IR (thin film, KBr): 3066 (w), 3034 (w), 2981 (w), 2936 (w), 1712 (s), 1672 





H NMR (400 MHz, CDCl3): δ 7.37 – 7.26 (m, 5H), 7.04 (d, J = 2.5 Hz, 1H), 6.18   
(s, 1H), 5.06 (d, J = 2.6 Hz, 1H), 4.73 (d, J = 11.6 Hz, 1H), 4.69 (d, J = 11.6 Hz, 1H), 2.36        
(s, 3H), 1.71 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 194.3, 188.7, 156.4, 144.1, 139.1, 135.4, 
128.7, 128.4, 127.8, 121.5, 86.1, 86.0, 69.7, 27.8, 21.3. HRMS (ESI+): m/z calc’d for 
C17H17O4
+
: 285.1121. Found: 285.1122. 
Dimethyl 3-(benzyloxy)-1-methyl-4-oxo-8-oxabicyclo[3.2.1]octa-2,6-diene-6,7-dicarboxylate 
(2.27e). Dimer 2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and 
CH2Cl2 (0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction 
vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. 
Dimethyl acetylenedicarboxylate (422 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, 
and the reaction mixture was subjected to microwave irradiation at 100 ºC for 10 min. The 
reaction mixture was then immediately purified by column chromatography (silica (10 g), 0% 
75  
EtOAc/hexane to 35% EtOAc/hexane gradient over 45 column volumes), giving 2.27e as a pale 
yellow solid (29.8 mg, 48% yield) and 2.4a as a yellow solid (5.2 mg, 11%). The 
1
H NMR for 
2.4a was consistent with previously reported data.
49a
 Characterization Data for 2.27e.             
MP = 104-107 ºC. Rf = 0.26 in 25% EtOAc in hexanes. IR (thin film, KBr): 3066 (w), 3034 
(w), 2954 (w), 1721 (s), 1652 (w), 1605 (m), 1455 (w), 1437 (m), 1323 (m), 1287 (s), 1124 (m), 




H NMR (400 MHz, CDCl3): δ           
7.39 – 7.28 (m, 5H), 6.09 (s, 1H), 5.26 (s, 1H), 4.78 (s, 2H), 3.87 (s, 3H), 3.79 (s, 3H), 1.64      
(s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 186.8, 163.8, 161.5, 153.5, 144.3, 136.0, 135.2, 128.7, 
128.4, 127.8, 119.9, 87.9, 86.8, 69.9, 52.9, 52.8, 20.9. HRMS (ESI+): m/z calc’d for C19H19O7
+
: 
359.1125. Found: 359.1130. 
3-(Benzyloxy)-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27f). Dimer  
2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2    
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,       
0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for 12 h. Phenyl acetylene 
(378 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture was 
subjected to microwave irradiation at 100 ºC for 30 min. The reaction mixture was then 
immediately purified by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x 
1.8 cm, solvent gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in 
hexanes (100 mL); 7% EtOAc in hexanes (200 mL); 10% EtOAc in hexanes (100 mL)). Product 
fractions concentrated to give 2.27f as a white solid (21.9 mg, 40% yield). MP = 112-114 ºC.    
Rf = 0.24 in 15% EtOAc in hexanes. IR (thin film, KBr): 3061 (w), 3033 (w), 2979 (w), 2933 
(w), 1709 (s), 1604 (s), 1491 (m), 1454 (m), 1339 (m), 1263 (m), 1125 (s), 1106 (m), 1058 (m), 




H NMR (400 MHz, CDCl3): δ 7.40 – 7.27 (m, 8H), 7.18 – 7.12 
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(m, 2H), 6.27 (d, J = 2.4 Hz, 1H), 6.24 (s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 4.92 (d, J = 12.0 Hz, 
1H), 4.79 (d, J = 12.0 Hz, 1H), 1.62 (s, 3H). 
13
C NMR (50 MHz, CDCl3): δ 189.9, 158.9, 144.7, 
135.6, 133.1, 128.8, 128.7, 128.3, 127.5, 126.0, 123.2, 121.6, 86.5, 86.1, 69.7, 22.0. HRMS 
(ESI+): m/z calc’d for C21H19O3
+
: 319.1329. Found: 319.1332. 
5-Methyl-3-((4-methylbenzyl)oxy)-6-(4-(trifluoromethyl)phenyl)-8-oxabicyclo[3.2.1]octa-
3,6-dien-2-one (2.27g). Dimer 2.24a (25 mg, 0.0892 mmol), 4-methylbenzyl alcohol (105 mg, 
0.860 mmol, 9.6 equiv.), and CH2Cl2 (0.26 M, 344 μL) were placed in a sealed tube reactor 
(Biotage
®
 microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in 
silicone oil bath for 12 h. 4-Ethynyl-α,α,α-trifluorotoluene (561 µL, 3.44 mmol, 39 equiv.) was 
added to the sealed tube, and the reaction mixture was subjected to microwave irradiation at   
100 ºC for 35 min. The reaction was then immediately purified by column chromatography 
(silica (10 g), 0% EtOAc/hexane to 15% EtOAc/hexane gradient over 25 column volumes), 
giving 2.27g as a yellow solid (30.2 mg, 42% yield). MP = 115-119 ºC. Rf = 0.31 in 15% EtOAc 
in hexanes. IR (thin film, KBr): 3054 (w), 2982 (w), 2936 (w), 1712 (m), 1615 (m), 1603 (m), 





H NMR (400 MHz, CDCl3): δ 7.57 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.19   
(d, J = 8.0 Hz, 2H), 7.13 (d, J = 7.9 Hz, 2H), 6.36 (d, J = 2.4 Hz, 1H), 6.18 (s, 1H), 5.02           
(d, J = 2.5 Hz, 1H), 4.93 (d, J = 12.1 Hz, 1H), 4.76 (d, J = 12.1 Hz, 1H), 2.32 (s, 3H), 1.59        
(s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 189.6 (s), 157.8 (s), 144.5 (s), 138.1 (s), 136.8           
(d, J = 1.2 Hz), 132.5 (s), 130.6 (q, J = 32.7 Hz), 129.5 (s), 127.5 (s), 126.3 (s), 125.7                
(q, J = 3.8 Hz), 125.6 (s), 124.0 (q, J = 272.1 Hz), 121.4 (s), 86.5 (s), 86.3 (s), 69.7 (s), 21.9 (s), 
21.2 (s). HRMS (ESI+): m/z calc’d for C23H19F3O3Na
+
: 423.1179. Found: 423.1182. 
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6-(4-Methoxyphenyl)-5-methyl-3-((4-(trifluoromethyl)benzyl)oxy)-8-oxabicyclo[3.2.1]octa-
3,6-dien-2-one (2.27h). Dimer 2.24a (25 mg, 0.0892 mmol), 4-(trifluoromethyl)benzyl alcohol 
(118 μL, 0.860 mmol, 9.6 equiv.), and CH2Cl2 (0.26 M, 344 μL) were placed in a sealed tube 
reactor (Biotage
®
 microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated to   
60 ºC in silicone oil bath for 4 h. 4-Ethynylanisole (446 µL, 3.44 mmol, 39 equiv.) was added to 
the sealed tube, and the reaction mixture was subjected to microwave irradiation at 100 ºC for  
40 min. The reaction was then immediately purified by column chromatography (silica (10 g), 
0% EtOAc/hexane to 20% EtOAc/hexane gradient over 30 column volumes), giving product 
contaminated with aryl alcohol. The aryl alcohol was removed with vacuum distillation, giving 
2.27h as a yellow oil (34.1 mg, 46% yield). Rf = 0.23 in 20% EtOAc in hexanes. IR (thin film, 
KBr): 3055 (w), 2977 (w), 2937 (w), 1711 (s), 1607 (m), 1510 (s), 1457 (w), 1326 (s), 1253 (s), 




H NMR (400 MHz, 
CDCl3): δ 7.60 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 8.6 Hz, 2H), 6.86       
(d, J = 8.6 Hz, 2H), 6.19 (s, 1H), 6.16 (d, J = 1.8 Hz, 1H), 4.99 (d, J = 2.1 Hz, 1H), 4.97           
(d, J = 13.5 Hz, 1H), 4.83 (d, J = 12.7 Hz, 1H), 3.82 (s, 3H), 1.62 (s, 3H). 
13
C NMR (100 MHz, 
CDCl3): δ 189.7 (s), 160.2 (s), 158.5 (s), 144.5 (s), 139.8 (q, J = 1.1 Hz), 130.5 (q, J = 32.5 Hz), 
127.5 (s), 127.3 (s), 125.8 (q, J = 3.7 Hz), 125.4 (s), 124.1 (q, J = 272.1 Hz), 122.1 (s), 121.0 (s), 
114.3 (s), 86.4 (s), 86.0 (s), 68.8 (s), 55.5 (s), 22.1 (s). HRMS (ESI+): m/z calc’d for 
C23H20F3O4
+
: 417.1308. Found: 417.1310. 
Ethyl 3-(benzyloxy)-5-(methoxymethyl)-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6- 
carboxylate (2.27i). Dimer 2.24b (29 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 
10 equiv.), and CH2Cl2 (0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 
microwave reaction vial, 0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for 
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12 h. Ethyl propiolate (349 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the 
reaction mixture was subjected to microwave irradiation at 100 ºC for 20 min. The reaction 
mixture was then immediately purified by column chromatography (silica (10 g), 0% 
EtOAc/hexane to 30% EtOAc/hexane gradient over 35 column volumes), yielding 2.27i as a 
white solid (31.8 mg, 54% yield) and 2.4i as a yellow oil (9 mg, 20%). Characterization Data for 
2.27i. MP = 80-84 ºC. Rf = 0.30 in 30% EtOAc in hexanes. IR (thin film, KBr): 3065 (w), 2983 
(w), 2931 (w), 1712 (s), 1617 (w), 1604 (m), 1455 (w), 1370 (w), 1320 (m), 1278 (w), 1217 (m), 




H NMR (400 MHz, CDCl3): δ           
7.37 – 7.27 (m, 5H), 7.12 (d, J = 2.4 Hz, 1H), 6.09 (s, 1H), 5.12 (d, J = 2.4 Hz, 1H), 4.78          
(d, J = 11.6 Hz, 1H), 4.73 (d, J = 11.6 Hz, 1H), 4.30 – 4.18 (m, 2H), 3.97 (d, J = 10.9 Hz, 1H), 
3.93 (d, J = 11.0 Hz 1H), 3.44 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3): δ 
188.4, 162.7, 147.5, 145.2, 139.0, 135.3, 128.7, 128.4, 127.8, 116.8, 88.4, 86.4, 72.2, 69.8, 61.4, 
59.8, 14.3. HRMS (ESI+): m/z calc’d for C19H21O6
+
: 345.1333. Found: 345.1334. 
Characterization Data for 2.4i. Rf = 0.27 in 35% EtOAc in hexanes. IR (thin film, KBr): 3067 
(w), 2982 (w), 2935 (w), 1712 (s), 1618 (m), 1607 (m), 1455 (w), 1319 (m), 1218 (m), 1120 (s), 




H NMR (400 MHz, CDCl3): δ 
7.11 (d, J = 2.5 Hz, 1H), 6.01 (s, 1H), 5.10 (d, J = 2.5 Hz, 1H), 4.25 (q, J = 7.0 Hz, 2H), 4.00   
(d, J = 10.9 Hz, 1H), 3.97 (d, J = 10.8 Hz, 1H), 3.57 (s, 3H), 3.45 (s, 3H), 1.32 (t, J = 7.1 Hz, 
3H). 
13
C NMR (100 MHz, CDCl3): δ 188.7, 162.8, 147.7, 146.3, 138.9, 115.0, 88.4, 86.2, 72.3, 
61.4, 59.9, 54.9, 14.3. HRMS (ESI+): m/z calc’d for C13H17O6
+
: 269.1020. Found: 269.1024. 
Ethyl 5-methyl-3-(neopentyloxy)-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate  
(2.27j). Dimer 2.24a (25 mg, 0.0892 mmol), neopentyl alcohol (76 mg, 0.860 mmol, 9.6 equiv.), 
and CDCl3 (0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction 
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vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Ethyl 
propiolate (349 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture 
was subjected to microwave irradiation at 100 ºC for 20 min. The reaction mixture was then 
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 25% 
EtOAc/hexane gradient over 25 column volumes), giving 2.27j as a yellow solid (29.8 mg, 57% 
yield) and 2.4d as a yellow solid (10.9 mg, 26% yield). The 
1
H NMR for 2.4d was consistent 
with previously reported data.
49a
 Characterization Data for 2.27j. MP = 69-73 °C. Rf = 0.31 in 
10% EtOAc in hexanes. IR (thin film, KBr): 3066 (w), 2958 (m), 2870 (w), 1712 (s), 1616 (m), 





H NMR (400 MHz, CDCl3): δ 7.09 (d, J = 2.5 Hz, 1H), 6.02 (s, 1H), 4.99        
(d, J = 2.5 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 3.26 (d, J = 8.9 Hz, 1H), 3.21 (d, J = 8.9 Hz, 1H), 
1.75 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H), 0.96 (s, 9H). 
13
C NMR (100 MHz, CDCl3): δ 188.7, 
163.1, 149.6, 144.8, 138.9, 119.7, 86.2, 85.6, 77.2, 61.2, 31.8, 26.7, 21.5, 14.3. HRMS (ESI+): 
m/z calc’d for C16H23O5
+
: 295.1540. Found: 295.1542. 
5-Methyl-3-(neopentyloxy)-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27k). Dimer 
2.24a (25 mg, 0.0892 mmol), neopentyl alcohol (76 mg, 0.860 mmol, 9.6 equiv.), and CDCl3 
(0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,       
0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Phenyl 
acetylene (378 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture 
was subjected to microwave irradiation at 100 ºC for 1 h. The reaction was then immediately 
purified by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x 1.8 cm, 
solvent gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 3% EtOAc in hexanes   
(100 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL)). Product 
80  
fractions were concentrated to give 2.27k as a yellow solid (22.9 mg, 43% yield) and 2.4f as a 
yellow solid (3.2 mg, 7% yield). The 
1
H NMR for 2.4f was consistent with previously reported 
data.
49a
 Characterization Data for 2.27k. MP = 114-117 °C. Rf = 0.33 in 10% EtOAc in hexanes. 
IR (thin film, KBr): 3057 (w), 2957 (m), 2869 (w), 1714 (s), 1603 (m), 1478 (w), 1446 (w), 
1365 (w), 1338 (w), 1260 (w), 1130 (m), 1059 (w), 995 (w), 865 (m), 755 (m), 697 (w) cm
-1
.   
1
H NMR (400 MHz, CDCl3): δ 7.42 – 7.27 (m, 5H), 6.29 (d, J = 2.4 Hz, 1H), 6.14 (s, 1H), 4.97   
(d, J = 2.5 Hz, 1H), 3.34 (d, J = 8.8 Hz, 1H), 3.25 (d, J = 8.8 Hz, 1H), 1.67 (s, 3H), 0.99 (s, 9H). 
13
C NMR (100 MHz, CDCl3): δ 189.7, 158.7, 145.7, 133.3, 128.8, 128.7, 126.1, 123.3, 119.4, 
86.5, 86.1, 77.3, 31.8, 26.7, 22.2. HRMS (ESI+): m/z calc’d for C19H23O3
+
: 299.1642. Found: 
299.1645. 
3-((1-Methyl-4-oxo-7-phenyl-8-oxabicyclo[3.2.1]octa-2,6-dien-3-yl)oxy)propanenitrile 
(2.27l). Dimer 2.24a (25 mg, 0.0892 mmol), 3-hydroxypropionitrile (59 μL, 0.860 mmol,        
9.6 equiv.), and CDCl3 (0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 
microwave reaction vial, 0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for 
12 h. Phenyl acetylene (378 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the 
reaction mixture was subjected to microwave irradiation at 100 ºC for 35 min. The reaction 
mixture was then immediately purified by column chromatography (silica (10 g), 0% 
EtOAc/hexane to 40% EtOAc/hexane gradient over 30 column volumes), giving 2.27l as an 
orange oil (21.1 mg, 42% yield) and 2.4f as a yellow solid (9.6 mg, 22%). The 
1
H NMR for 2.4f 
was consistent with previously reported data.
49a
 Characterization Data for 2.27l. Rf = 0.24 in 
35% EtOAc in hexanes. IR (thin film, KBr): 3058 (w), 2979 (w), 2937 (w), 2253 (w), 1710 (s), 
1606 (m), 1492 (w), 1446 (w), 1342 (w), 1264 (w), 1132 (s), 1057 (m), 878 (m), 864 (m), 755 




H NMR (400 MHz, CDCl3): δ 7.43 – 7.33 (m, 3H), 7.30 – 7.23 (m, 2H), 
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6.32 (s, 1H), 6.29 (d, J = 2.4 Hz, 1H), 5.00 (d, J = 2.5 Hz, 1H), 4.05 – 3.87 (m, 2H), 2.81           
(t, J = 6.8 Hz, 2H), 1.68 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 189.2, 158.5, 144.3, 132.9, 
129.0, 128.9, 126.1, 123.2, 122.7, 116.7, 86.4, 86.0, 62.7, 22.0, 18.2. HRMS (ESI+): m/z calc’d 
for C17H15NO3Na
+
: 304.0944. Found: 304.0948.  
3-Isopropoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27m). Dimer  
2.24a (25 mg, 0.0892 mmol), isopropyl alcohol (66 μL, 0.860 mmol, 9.6 equiv.), and CDCl3 
(0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,       
0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 36 h. Phenyl 
acetylene (378 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture 
was subjected to microwave irradiation at 100 ºC for 1 h. The reaction mixture was then 
immediately purified by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x 
1.8 cm, solvent gradient: hexanes (50 mL); 5% EtOAc in hexanes (100 mL); 8% EtOAc in 
hexanes (100 mL); 10% EtOAc in hexanes (100 mL), 15% EtOAc in hexanes (100 mL)). 
Product fractions were concentrated to give 2.27m as a yellowish oil (15.3 mg, 32% yield) and 
2.4f as a yellowish solid (11.3 mg, 26% yield). The 
1
H NMR for 2.4f was consistent with 
previously reported data.
49a
 Characterization Data for 2.27m. Rf = 0.27 in 15% EtOAc in 
hexanes. IR (thin film, KBr): 3057 (w), 2979 (m), 2935 (w) 1710 (s), 1600 (s), 1596 (s), 1493 





H NMR (400 MHz, CDCl3): δ 7.42 – 7.31 (m, 3H), 7.30 – 7.25 (m, 2H), 6.28                
(d, J = 2.4 Hz, 1H), 6.19 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 4.24 (sept, J = 6.1 Hz, 1H), 1.66       
(s, 3H), 1.32   (d, J = 6.1 Hz, 3H), 1.25 (d, J = 6.0 Hz, 3H). 
13
C NMR (50 MHz, CDCl3): δ 
190.7, 158.8, 143.8, 133.3, 128.9, 128.7, 126.1, 123.4, 121.1, 86.5, 86.1, 69.9, 22.2, 21.5. HRMS 
(ESI+): m/z calc’d for C17H19O3
+
: 271.1329. Found: 271.1331. 
82  
3-(Allyloxy)-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27n). Dimer 2.24a 
(25 mg, 0.0892 mmol), allyl alcohol (58 μL, 0.860 mmol, 9.6 equiv.), and CDCl3 (0.26 M,      
344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 0.5-2 mL), and 
the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Phenyl acetylene (378 µL, 
3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture was subjected to 
microwave irradiation at 100 ºC for 30 min. The reaction mixture was then immediately purified 
by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x 1.8 cm, solvent 
gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in hexanes (100 mL); 
7% EtOAc in hexanes (150 mL); 10% EtOAc in hexanes (50 mL); 15% EtOAc in hexanes    
(100 mL)). Product fractions were concentrated to give 2.27n as yellowish oil (11.5 mg, 24% 
yield) and 2.4f as yellowish solid (5.2 mg, 12% yield). The 
1
H NMR for 2.4f was consistent with 
previously reported data.
49a
 Characterization Data for 2.27n. Rf = 0.24 in 15% EtOAc in 
hexanes. IR (thin film, KBr): 3081 (w), 3057 (w), 2981 (w), 2935 (w), 1710 (s), 1603 (s), 1491 





H NMR (400 MHz, CDCl3): δ 7.41 – 7.32 (m, 3H), 7.29 – 7.25 (m, 2H), 6.28                
(d, J = 2.5 Hz, 1H), 6.21 (s, 1H), 6.02-5.91 (m, 1H), 5.35 (dq, J = 17.3, 1.5 Hz, 1H), 5.27        
(dq, J = 10.5, 1.3 Hz, 1H), 4.99 (d, J = 2.5 Hz, 1H), 4.34 (ddt, J = 12.6, 5.4, 1.4 Hz, 1H), 4.26 
(ddt, J = 12.7, 5.6, 1.3 Hz, 1H), 1.66 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 190.0, 158.8, 
144.7, 133.2, 132.1, 128.84, 128.80, 126.1, 123.3, 120.8, 118.7, 86.5, 86.1, 68.6, 22.2. HRMS 
(ESI+): m/z calc’d for C17H16O3Na
+
: 291.0992. Found: 291.0997. 
3-(Benzyloxy)-6-(4-ethynylphenyl)-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27o).  
Dimer 2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2 
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,       
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0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 14 h. 
1,4-Diethynylbenzene (217 mg, 1.72 mmol, 20 equiv.) and CH2Cl2 (344 μL) were added to the 
sealed tube, and the reaction mixture was stirred until no solid was observed. The reaction 
mixture was then subjected to microwave irradiation at 100 ºC for 35 min and immediately 
purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 15% EtOAc/hexane 
gradient over 30 column volumes). Product fractions were concentrated to give 2.27o as an 
orange oil (25.7 mg, 44% yield). Due to high value of 1,4-diethynylbenzene (2.28), fractions 
containing it were also concentrated (174 mg, 89% recovery (195 mg would be 100% theoretical 
yield of un-reacted product)). Rf = 0.28 in 15% EtOAc in hexanes. IR (thin film, KBr): 3287 
(m), 3035 (w), 2981 (w), 2935 (w), 2106 (w), 1709 (s), 1600 (m), 1498 (m), 1455 (m), 1339 (m), 




H NMR (400 MHz, CDCl3): δ 
7.45 (d, J = 8.4 Hz, 2H), 7.35 – 7.27 (m, 5H), 7.08 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 2.5 Hz, 1H), 
6.19 (s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 4.93 (d, J = 12.1 Hz, 1H), 4.78 (d, J = 12.1 Hz, 1H), 3.15 
(s, 1H), 1.60 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 189.7, 158.2, 144.7, 135.6, 133.6, 132.5, 
128.8, 128.3, 127.5, 126.0, 124.3, 122.5, 121.4, 86.4, 86.2, 83.2, 78.6, 69.7, 22.0. HRMS 
(ESI+): m/z calc’d for C23H18O3Na
+
: 365.1148. Found: 365.1150. 
Synthesis of α-Hydroxytropolones via Acid-Mediated Debenzylation: Procedure A. To a 
solution of 2.27f (25.6 mg, 0.0804 mmol) in CH2Cl2 (500 μL) was added methanesulfonic acid 
(210 μL, 3.22 mmol, 40 equiv.). The reaction mixture was stirred for 1 h, at which time it was 
quenched with phosphate buffer (pH 7, 15 mL), extracted with CH2Cl2 (3 x 10 mL), dried over 
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.6a as a reddish brown oil 
(19.0 mg, >95% crude yield). The 
1





H NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.50 (s, 1H), 7.48 – 7.35 (m, 3H),           
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7.25 – 7.21 (m, 2H), 2.26 (s, 3H). Procedure B. To a solution of 2.27f (25 mg, 0.0785 mmol) in 
CH2Cl2 (1 mL) was added Amberlyst
®
 15 (4.7 mmol/g, 671 mg, 3.14 mmol, 40 equiv.). The 
reaction mixture was stirred for 16 h, at which time the Amberlyst was washed with CH2Cl2      
(5 x 2 mL). The Amberlyst was then stirred in phosphate buffer (pH 7, 15 mL) for 10 min, and 
the aqueous layer was extracted with EtOAc (5 x 10 mL). Combined organics were dried over 
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.6a as a light brown oil       
(11.6 mg, 65% yield). The 
1
H NMR for 2.6a was consistent with previously reported data.
55       
1
H NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.50 (s, 1H), 7.48 – 7.35 (m, 3H), 7.25 – 7.21     
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Chapter III 
A Traceless Solid-Phase Synthesis of α-Hydroxytropolones 
3.1. Solid-Supported Synthesis of Small Molecule Libraries 
 Solid-phase organic synthesis (SPOS), in which compounds are assembled on insoluble 
polymer resin beads, has revolutionized synthetic organic chemistry since first introduced by 
Merrifield in 1963.
40a,74
 Solid-phase techniques possess two major advantages over traditional 
procedures in solution. First, resin-bound products can simply be isolated by washing away 
reagents or impurities from the supported material, allowing the use of excess reagents to drive 
reactions to completion. Secondly, the overall time scale for solid-phase synthesis is significantly 
reduced due to its ease of purification and amenability to automation. Though primarily 
associated with peptide, nucleic acid, and carbohydrate chemistry, solid supports have been 
utilized in the combinatorial synthesis of small molecule drugs and natural products. To gain 
access to these compound libraries, novel polymer resins, traceless linkers, and automated 
technologies were discovered and developed. These solid-phase strategies and innovations are 
extensively detailed in several reviews,
40a,74
 and hence the current discussion will highlight only 
a few examples.  
3.1.1. Ellman’s Library Synthesis of 1,4-Benzodiazepin-2-ones 
1,4-Benzodiazepin-2-ones are the class of compounds in which the term “privileged 
scaffold’ was first applied.
41
 Though they demonstrate an expansive therapeutic profile that 
includes coronary vasodilation and viral inhibition, most of the biological activity of these 
molecules can be attributed to their effects on the central nervous system.
75
 In one of the first 
reports outlining the combinatorial synthesis and biological testing of small molecule libraries, 




The compound collection was constructed by initially attaching 
aminobenzophenone derivatives to a solid support via a (4-(hydroxymethyl)phenoxy)acetic acid 
(HMP) linker (3.1 → 3.2).
76,77
 The resin-bound intermediate 3.2 was then reacted with Fmoc-
protected amino acid fluoride to create compound 3.3. After Fmoc deprotection, ring closure on 
3.3 was induced by an acid-mediated condensation reaction, giving molecule 3.4. Alkylation of 
anilide 3.4 was achieved in the presence of lithiated 5-phenylmethyl-2-oxazolidinone.
76
 Finally, 
the 1,4-benzodiazepine with four points of functionality was cleaved in acidic conditions. The 
Ellman group prepared a 192-member library using this synthetic route and performed biological 
screening on targets such as cholecystokinin (CCK) receptor A, which is a protein implicated in 
gastrointestinal cancer, neuroprotection, and appetite satiety.
76b
 The work would stimulate 





3.1.2. Nicolaou’s Combinatorial Synthesis of 2,2-Dimethylbenzopyrans 
 At the turn of the millennium, Nicolaou and co-workers reported an extremely thorough 
combinatorial synthesis of the privileged substructure 2,2-dimethylbenzopyrans.
42
 Natural 
products with the benzopyran structural motif exhibit antitumor, antimicrobial, and anti- 
inflammtory activity and interact with a plethora of biological targets.
40a,42a,78,79
 The synthetic 
strategy implemented by the Nicolaou group entails the attachment of an ortho-prenylated 
phenol (3.7) to a polymer support through a traceless selenium linker (Scheme 3.2).
42
 The 
resulting resin-bound intermediate 3.8 then undergoes a 6-endo-trig cyclization to furnish the 
benzopyran core (3.9), which can be derivatized using an array of chemical modifications (e.g. 
organometallic additions, condensations, annulations, etc.). The compound is finally cleaved via 
selenium oxidation, which facilitates a spontaneous syn-elimination at room temperature to 
produce the benzopyran product (3.10 → 3.12). Nicolaou and coworkers would go on to 
generate a 10,000-member library of these molecules in just eight days by combining the 
129  
traceless solid-phase route with optically encoded split-and-pool techniques.
42b
 Biological 
evaluation of the benzopyran library revealed a high hit rate for a diverse range of targets.
79
 
3.1.3. Merck’s Solid-Phase Synthesis of 2-Arylindole Derivatives 
 The indole structure is a near-ubiquitous subunit of biologically active natural products 
and pharmaceuticals, and the scope of its physiological effects is astronomical. Considering its 
vast therapeutic potential, a number of research groups have described combinatorial syntheses 
towards indole-derived drugs.
40a,74
 For example, Merck reported the construction of a 128,000-
member 2-arylindole library in order to search for G-protein-coupled receptor (GPCR) ligands.
80
 
The group’s synthetic strategy initially entailed the anchoring of arylalkyl keto acids to a 
sulfonamide resin (3.13 → 3.14, Scheme 3.3). The indole core was then generated through a 
cyclization reaction with arylhydrazines in the presence of a Lewis acid (i.e. Fischer indole 
synthesis).
80,81
 At this stage, up to 400 unique combinations for 3.15 were possible due to the 
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incorporation of 20 distinct derivatives of each building block. The resin-bound molecule was 
separated into 80 equal portions, where the sulfonamides were subsequently alkylated with 
Mitsunobu conditions and displaced by 80 individual amines (3.15 → 3.16). After recombining 
the compound pools (now with 32,000 possibilities), it was split into two equal portions, 
whereby 128,000 molecules were produced through the creation of one library containing amides 
(3.16) and the other consisting of amines (3.17). Physiological evaluation of the 2-arylindoles 
resulted in multiple hits for several GPCRs, and led Merck to advance the program towards the 
discovery of clinical candidates.
80
  
3.2. The Solid-Phase Synthesis of αHTs 
3.2.1. Leveraging Three-Component Oxidopyrylium Cycloaddition to Incorporate Solid Supports 
As discussed previously, our laboratory discovered a three-component oxidopyrylium 
cycloaddition that generates new oxabicyclic products through alcohol incorporation into 
oxidopyrylium ylides (3.18 → 3.20, Scheme 3.4A).
71
 Furthermore, benzyl alcohol-derived 
oxabicyclic intermediates generated from this reaction can be directly converted to αHTs when 
subjected to methanesulfonic acid (3.20 → 3.21g). Given the prevalence of solid supports in 
organic synthesis (reviewed above), we integrated a polystyrene-bound benzyl alcohol into our 
αHT route by utilizing the three-component oxidopyrylium cycloaddition (Scheme 3.4B).
82
 This 
resin possesses a major advantage over more widely used derivatives, such as Wang resin, in that 
no additional components appear in solution upon cleavage (i.e. traceless). Therefore, the entire 
procedure grants access to assay-ready compounds without necessitating column 
chromatography.   
The protocol was conducted in a sealed vessel, where polystyrene-supported benzyl 
alcohol was lightly stirred in a solution of triflate salt 3.24 and base at 60 
o
C overnight (Table 
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3.1). We speculate that this initial phase forms an oxidopyrylium heterodimer (3.25c and/or 
3.25d) according to the known rapid dimerization processes of oxidopyrylium ylides.
49a
 
However, more mechanistic data is required to eliminate the possibility that the cross-linked 
homodimer 3.25b acts as an intermediate. After completion of the overnight alcohol 
incorporation, an on-bead cycloaddition was facilitated by heating the reaction mixture at 100 
o
C 
in the presence of alkynes (3.24 → 3.23).
82
 For liquid alkynes, the solvent and solutes were 
removed from the system prior to alkyne addition to increase the efficiency of the reaction 
(Table 3.1, Procedure A). On the other hand, solid alkynes were directly added to the mixture 
without expelling the solvent and solutes to allow for dissolution of the reagent (Procedure B). 
The optimal cycloaddition reaction times were dictated by alkyne reactivity, as insufficient time 
points gave increased amounts of allomaltol (3.26). Procedures with electronically poor alkynes 




































R = COMe 
R = COMe 
R = COMe 
R = COCy 
R = COPh 
R = COPh 
R = CO(4-Ph)Ph 
R = CO2Et 
R = CO2Et 
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8% 3.21a (9:1:0) 
7% 3.21a 
4% 3.21a (9:1:0) 
11% 3.21b (15:1:4) 
22% 3.21c (1:0:1) 
6% 3.21c (5:0:1) 






7% 3.21g (9:1:0) 
13% 3.21g (20:1:0) 
6% 3.21g (5:1:0) 
11% 3.21h (4:1:0) 
6% 3.21h (4:1:0) 
7% 3.21i (5:1:0) 
6% 3.21i (15:1:0) 
10% 3.27j 
[a] CH2Cl2 and solutes not removed prior to addition of alkyne. [b] Time for step 2. [c]
 
Reaction ran at twice 
the scale of prior run.  [d] DMAD = Dimethyl acetylenedicarboxylate. 
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hours of heating for maximum output. Lastly, besides allomaltol and trace baseline 
contaminants, furan byproducts (3.27) emerging from acid-mediated ring-opening/cleavage were 
the only other impurities observed. As expected from previous reports, furan 3.27j was the major 
product when dimethyl acetylenedicarboxylate (DMAD) was used for the process.
49b
  
From 33 mg of polystyrene-supported benzyl alcohol and 50 mg of triflate salt 3.24, 
between 1-5 mg of various αHTs were obtained, corresponding to approximately 5-10% yield 
based on resin loading (Table 3.1).
82
 Though large quantities of alkyne (400-500 mg) were 
required for the cycloaddition reaction, the overall process is highly time efficient and bypasses 
the need for chromatographic purification. As many as 8 αHTs were generated in parallel over a 
single 24 hour period during our studies, with enough material being collected to determine 
product formation and purity level by 
1
H NMR and perform several bioassays. Thus, despite the 
low overall yields, the protocol may serve as an important tool in the rapid library synthesis of 
αHTs for biological screening purposes. 
3.2.2. Utilizing Solid-Phase αHT Synthesis as a Screening Tool for Biological Studies 
Considering that αHTs are capable of binding to and inhibiting a variety of dinuclear 
metalloenzymes,
44
 we directed our focus towards applying the solid-phase platform as a 
screening tool for discovering potent inhibitors. A very promising target for αHTs is HIV 
ribonuclease H (RNase H), against which the natural products β-thujaplicinol and manicol have 
illustrated IC50 values of 200 nM and 600 nM, respectively.
45a,45e
 HIV RNase H is an enzyme 
located on the C-terminal domain of HIV reverse transcriptase (RT).
83
 The RNase H active site 
works in conjunction with the DNA polymerase of HIV RT to facilitate viral genomic 
replication. Though a majority of treatments on the market inhibit the polymerase activity, the 
RNase H domain remains clinically unexploited. However, due to the emergence of resistant 
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viral variants, significant efforts are underway to identify viable drug candidates for HIV RNase 
H.
84
 Our newly developed solid-supported synthesis has potential utility towards the increased 
throughput of αHT-derived leads for this enzyme. Thus, we experimentally evaluated the assay-
ready nature of the solid-supported library against HIV RNase H.
82
 
 In collaboration with Le Grice and co-workers, we began by measuring αHT inhibition 
with a fluorescence resonance energy transfer (FRET) endpoint to monitor the RNase H activity 
of HIV-1 RT (Figure 3.1).
85
 A majority of the compounds possessed a consistent inhibitory 
potency, with typical IC50 values between 200 nM and 1 μM. When compared to the solution 
phase counterparts, the solid-supported molecules were all within 2-3 fold difference, and also 



















R Group  
HIV RNase H inhibitory data for solution and solid-phase αHTs 
Figure 3.1. Plot of HIV RNase H inhibitory data for solution and solid-phase αHTs. 
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RNase H against thermal denaturation with the use of differential scanning fluorimetry 
(Thermofluor, Figure 3.2).
86
 Regardless of the corresponding impurities, all compounds 
increased the melting point of the enzyme by 2-3 
o
C.  In addition, those species that stabilized 
the enzyme the least did so in both solution and solid-phase cases. Lastly, the protective effects 
of the molecules were investigated in HIV-associated cellular assays.
87
 Only three derivatives 
(i.e. 3.21a, 3.21e, 3.21f) demonstrated protective activity, as the trend was consistent for both 
types of synthesis. Overall, these biological studies revealed that enzymatic and cell-based assays 
are not severely impacted by the minor impurities observed with samples prepared from solid-
supported chemistry. Hence, the synthetic method produces αHTs with assay-ready purity and 


















HIV RNase H thermal stabilization assays for solution and 
solid-phase αHTs 
Figure 3.2. Plot of HIV RNase H thermal stabilization data for solution and solid-phase αHTs. 
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3.2.3. Limitations of Solid-Supported αHT Synthesis 
 The proof-of-principle synthetic and biological experiments outlined above illustrate that 
the solid-supported platform is extremely time efficient and generates compounds with assay-
ready purity. Nevertheless, improvements to the system are necessary for it to be completely 
viable as a combinatorial technique for αHT synthesis. First, though yields for the process are 
practical for biological screening, they are substantially low overall (i.e. ~5-20% yield for 9 
substrates). These results are at least partially related to the heterogeneous nature of the reaction, 
which would make complete alcohol exchange during the three-component oxidopyrylium 
cycloaddition more difficult. For instance, prior optimization efforts for the solution phase 
process demonstrated considerable increases in productivity when the purified dimer 3.25a 
served as the ylide source.
71
 No such yield increases were observed when this strategy was 
employed for the solid-supported synthesis (Scheme 3.5).
82
  
 On the other hand, some advantages did emerge when 3.25a was used in place of the 
triflate salt/base combination. Through the elimination of the base, we easily recovered the 
starting material by simply removing the supernatant liquid and evaporating the solvent. 
Additionally, we could monitor the efficiency of incorporation by measuring the amount of 
dimer re-isolated. For example, in Reaction A of Scheme 3.5, 16 out of 24 mg of 3.25a were 
retrieved. Assuming that the remaining 8 mg of material is attached to the solid-support as 
heterodimer, approximately half of that compound would be available for subsequent phases of 
the synthetic sequence. In light of this data, the dimer concentration was increased to 4 equiv.   
(8 equiv. based on monomeric ylide), and the incorporation step was stirred at room temperature 
for 9 days (Scheme 3.5, Reaction B). We recovered 87% of 3.25a (104 out of 120 mg), and 
improved our yields to 20% based on resin loading, providing some direction for future attempts 
at optimization.  
137  
 Another major issue with the solid-phase platform is the inability to modify resin-bound 
intermediates. Efforts at conducting chemical transformations on supported oxabicyclic 
compounds, including Suzuki coupling or trifluoroacetic acid (TFA) deprotection, resulted in 
unintended cleavage and no end product. These observations indicate that the polystyrene-bound 
oxabicycle is generally unstable. We hypothesize that the decomposition is due to the electron 
donating properties of the benzyl alcohol resin, which would potentially drive the intermediate 
towards detrimental side-reactions or early deprotection.
66a
 A possible solution to such a 
dilemma is the use of different resins and/or linkers to stabilize the attachment of the 
oxabicycle.
74c
 These studies are currently underway to improve the solid-supported αHT 
synthesis towards a completely functional combinatorial technique.  
3.3. Conclusion 
 Our laboratory has leveraged a newly discovered three-component oxidopyrylium 
cycloaddtion in the first reported solid-phase synthesis of αHTs. The method is extremely time 
efficient and produces molecules with assay-ready purity, making it a useful tool for therapeutic 
development. However, due to the low overall yields and an inability to modify on-bead, the 
system still requires improvements to meet its full potential. Though endeavors are presently 
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ongoing to address the issues with the solid-supported platform, the next chapter will detail an 
approach that bypasses these limitations. Specifically, the discussion will describe the 
incorporation of fluorous phase chemistry into our αHT route.  
3.4. Experimental and Supporting Information 
General Information: All starting materials and reagents were purchased from commercially 
available sources and used without further purification, with exception of CH2Cl2, which was 




H NMR shifts are measured using 
the solvent residual peak as the internal standard (CHCl3 δ 7.26), and reported as follows: 
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet 
of doublet, q = quartet, m = multiplet), coupling constant (Hz), integration. 
13
C NMR shifts are 
measured using the solvent residual peak as the internal standard (CDCl3 δ 77.16), and reported 
as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong (s), 
medium (m), and weak (w). Mass spectra were recorded on a spectrometer by electrospray 
ionization (ESI) technique and time-of-flight (TOF) mass analyzer. Microwave reactions were 
performed via the Biotage
®
 Intiator (External IR Temperature Sensor). Where noted, reaction 
products were purified via silica gel chromatography using a Biotage
® 
Isolera Prime, with 
Biotage
®
 SNAP 10 g cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane.  
Solution Phase Synthesis of 3-Methoxy-8-oxabicyclo[3.2.1]octenes: 
Methyl 3-methoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate (3.28f).  
Triflate salt 3.24 (100 mg, 0.345 mmol), N,N-diisopropylaniline (81 μL, 0.414 mmol,              
1.2 equiv.), and CH2Cl2 (0.46 M, 750 μL) were placed in a sealed tube reactor (Biotage
®
 
microwave reaction vial, 0.5-2 mL) and stirred until no solid was observed. Methyl propiolate 
(307 μL, 3.45 mmol, 10 equiv.) was added to the sealed tube, and the reaction mixture was 
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subjected to microwave irradiation at 100 ºC for 20 min. The reaction mixture was then 
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 35% 
EtOAc/hexane gradient over 22 column volumes), giving 3.28f as a yellow oil (54.8 mg, 71% 
yield). Rf = 0.29 in 25% EtOAc in hexanes.  IR (thin film, KBr): 3095 (w), 2954 (w), 2840 (w), 
1712 (s), 1616 (m), 1604 (m), 1438 (w), 1323 (m), 1223 (m), 1127 (m), 1075 (m), 1035 (w), 873 




H NMR (400 MHz, CDCl3): δ 7.06 (d, J = 2.5 Hz, 1H), 6.05        
(s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.76 (s, 3H), 3.52 (s, 3H), 1.73 (s, 3H). 
13
C NMR (100 MHz, 
CDCl3): δ 188.89, 163.49, 149.57, 145.27, 139.15, 119.53, 86.16, 85.75, 54.92, 52.32, 21.57. 
HRMS (ESI+): m/z calc’d for C11H13O5
+
: 225.0757. Found: 225.0757.  
Solution Phase Synthesis of α-Hydroxytropolones: 
Methyl 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate (3.21f).  
To a solution of bicycle 3.28f (54.8 mg, 0.244 mmol) in CH2Cl2 (0.16 M, 1.5 mL) was added 
trifluoromethanesulfonic acid (86.3 μL, 0.978 mmol, 4 equiv.). The reaction mixture was 
allowed to stir for 30 min, at which time it was quenched with phosphate buffer (pH 7, 10 mL), 
extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude mixture was then dissolved in 33% HBr in acetic acid (2 mL), and heated to 
reflux for 1.5 h. The reaction was cooled to room temperature, quenched with pH 7 phosphate 
buffer (10 mL), and extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4, filtered, and 
concentrated to give 3.21f as a brown solid (30.0 mg, 58% yield). MP = 137-141 °C. IR (thin 
film, KBr): 3239 (br), 2963 (w), 1731 (s), 1544 (s), 1435 (m), 1400 (m), 1288 (s), 1214 (s), 




H NMR (400 MHz, 
CDCl3): δ 7.73 (s, 1H), 7.48 (s, 1H), 3.93 (s, 3H), 2.56 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ  
169.30, 168.82, 159.40, 156.96, 141.27, 132.64, 124.60, 120.92, 53.22, 25.97. HRMS (ESI+): 
m/z calc’d for C10H11O5
+
: 211.0601. Found: 211.0602. 
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Solid-Phase Synthesis of α-Hydroxytropolones Using Oxidopyrylium Triflate Salt: 
General Procedure for Liquid Alkynes (Procedure A). Polystyrene supported benzyl alcohol   
(3.5 mmol/g loading capacity, 1 equiv.) was placed in a sealed tube reactor (Biotage
®
 microwave 
reaction vial, 2-5 mL) and allowed to swell for 30 min in CH2Cl2. Triflate salt 3.24 (1.5 equiv.) 
and N,N-diisopropylaniline (1.8 equiv.) were added to the sealed tube, and the reaction mixture 
was gently stirred at 60 ºC for 14 h. The beads were drained of CH2Cl2, submerged in alkyne, 
and heated to 100 ºC for various time points. After the reaction mixture was cooled to room 
temperature, the beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in CH2Cl2. 
Trifluoromethanesulfonic acid (4 equiv.) was added to the sealed tube, and the reaction mixture 
was stirred at room temperature for 30 min. The reaction mixture was diluted with CH2Cl2        
(2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL), and combined organics were dried over Na2SO4, filtered, and concentrated to 
give αHT 3.21. 
General Procedure for Solid Alkynes (Procedure B). Polystyrene supported benzyl alcohol     
(3.5 mmol/g loading capacity, 1 equiv.) was placed in a sealed tube reactor (Biotage
®
 microwave 
reaction vial, 2-5 mL) and allowed to swell for 30 min in CH2Cl2. Triflate salt 3.24 (1.5 equiv.) 
and N,N-diisopropylaniline (1.8 equiv.) were added to the sealed tube, and the reaction mixture 
was gently stirred at 60 ºC for 14 h. Alkyne was added to the sealed tube, and the reaction 
mixture was heated to 100 ºC for various time points. After the reaction mixture was cooled to 
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room temperature, the beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in 
CH2Cl2. Trifluoromethanesulfonic acid (4 equiv.) was added to the sealed tube, and the reaction 
mixture was stirred at room temperature for 30 min. The reaction mixture was diluted with 
CH2Cl2 (2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous layer was 
extracted with CH2Cl2 (3 x 5 mL), and combined organics were dried over Na2SO4, filtered, and 















































Solid-Phase Synthesis of α-Hydroxytropolones Using Oxidopyrylium Dimer: 
Procedure A. Polystyrene supported benzyl alcohol (3.5 mmol/g, 33 mg, 0.114 mmol, 1 equiv.) 
was placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL) and allowed to 
swell for 30 min in CH2Cl2. Oxidopyrylium dimer 3.25a (24 mg, 0.086 mmol, 0.74 equiv.) was 
added to the sealed tube, and the reaction mixture was gently stirred at 60 ºC for 14 h. The beads 
were rinsed with CH2Cl2 (6 x 1 mL), and the supernatant liquid was collected (16 mg of 3.25a, 
66% recovery). Ethyl propiolate (500 μL) was added to the sealed tube, and the reaction mixture 
was heated to 100 ºC for 1.5 h. After the reaction mixture was cooled to room temperature, the 
beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in CH2Cl2 (500 μL). 
Trifluoromethanesulfonic acid (41 μL, 0.464 mmol, 4 equiv.) was added to the sealed tube, and 
the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was 
diluted with CH2Cl2 (2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 5 mL), and combined organics were dried over Na2SO4, 
filtered, and concentrated to give 3.21e (1.5 mg, 6% yield). 
Procedure B. Polystyrene supported benzyl alcohol (3.5 mmol/g, 33 mg, 0.114 mmol, 1 equiv.) 
was placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL) and allowed to 
swell for 30 min in CH2Cl2. Oxidopyrylium dimer 3.25a (120 mg, 0.428 mmol, 3.8 equiv.) was 
added to the sealed tube, and the reaction mixture was gently stirred at 60 ºC for 14 h. The beads 
were rinsed with CH2Cl2 (6 x 1 mL), and the supernatant liquid was collected (104 mg of 3.25a, 
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87% recovery). Ethyl propiolate (500 μL) was added to the sealed tube, and the reaction mixture 
was heated to 100 ºC for 1.5 h. After the reaction mixture was cooled to room temperature, the 
beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in CH2Cl2 (500 μL). 
Trifluoromethanesulfonic acid (41 μL, 0.464 mmol, 4 equiv.) was added to the sealed tube, and 
the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was 
diluted with CH2Cl2 (2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 5 mL), and combined organics were dried over Na2SO4, 
filtered, and concentrated to give 3.21e (5 mg, 20% yield). 
145  













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A Fluorous Phase Approach to α-Hydroxytropolone Synthesis 
4.1. An Introduction to Fluorous Phase Chemistry 
 Synthesis is universally restricted by the efficiency of the reactions being performed and 
the ability to purify resultant mixtures. Though organic chemists have traditionally focused on 
the effectiveness of transformations in solution, a number of techniques have recently emerged 
that simplify purification. The most prevalent method entails the integration of solid supports 
into a synthetic sequence (reviewed in Chapter III).
40a,74
 A second, lesser known approach 
started in the 1990s utilizes the unique interactions between perfluorinated molecules and other 
reaction media (i.e. fluorous phase chemistry).
88
 Specifically, the higher the fluorine content a 
compound possesses, whether it be solvent or reactant, the more insoluble the species becomes in 
aqueous and organic environments (>60% typically produces complete partition).
89
 However, 
unlike in water, the miscibility of fluorous molecules in organic solvents depends on 
temperature, as heated systems become increasingly monophasic. This distinct solubility profile 
was pivotal to the early success of fluorous chemistry and has granted access to a plethora of 
novel linkers, catalysts, scavengers, and purification technologies.
88
 
4.1.1. The Major Advantages of Fluorous Phase Synthesis 
 Fluorous synthesis successfully incorporates solution phase reaction conditions with a 
phase-tag separation that relies on perfluoroalkyl chains instead of resins to facilitate 
purification.
88,90
 The fluorous tags are chemically stable and typically have minor influence on 
the reactivity of a molecule to which they are attached. In contrast to solid-phase synthesis, 
fluorous reactions can be monitored by conventional analytical techniques (e.g. TLC, NMR, IR, 
etc.) and can adapt literature procedures without severe alteration. Additionally, although 
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fluorous molecules can be isolated through traditional methods, including chromatography, 
distillation, and recrystallization, exclusive purification procedures exist that rely on selective 




The first approach takes advantage of the inherent immiscibility between fluorous 
solvents and other fluids to isolate individual reaction components, otherwise known as fluorous 
liquid-liquid extraction (FLLE, Figure 4.1A).
89
 Separations are generally achieved with 
organic/fluorous biphasic systems or organic/aqueous/fluorous triphasic extractions when water-
soluble reagents are used. Nevertheless, this process is geared toward heavier fluorous molecules 
(>60% fluorine content) since they demonstrate an optimal partition coefficient between organic 
and fluorous phases. Also, FLLE often requires expensive and environmentally destructive 
fluorous solvents, such as perfluoroalkanes, which could make it prohibitive for large-scale 
endeavors.      
184  
 The second purification method is a fluorous solid-phase extraction (FSPE, Figure 
4.1B).
91
 As the name implies, the procedure involves the use of a fluorinated solid-phase 
component, specifically in the form of fluorocarbon bonded silica gel (–SiMe2(CH2)2C8F17, 
FluoroFlash
®
). This stationary phase retains organic species to a much lower degree than 
ordinary reverse-phase silica. Hence, organic compounds will rapidly pass through the column 
with an appropriate eluent. On the other hand, the fluorous silica is extremely retentive to 
fluorinated molecules and can even partition compounds based on fluorine content. For instance, 
Curran employed FSPE to separate a series of molecules containing fluorous tags that ranged 
from C3F7 to C10F21.
91a
 However, the approach does not necessitate fluorous solvents to elute 
reaction mixtures, as common organic and aqueous solvent media will suffice.
91
 In particular, 
nonfluorous compounds are eluted with fluorophobic solutions, such as 60% acetonitrile (ACN) 
in H2O or 80% methanol (MeOH) in H2O, while MeOH or acetone will pass fluorinated species 
through the column. Additionally, the fluorous silica can be recycled dozens of times, making 
FSPE a more economically and environmentally friendly purification strategy than FLLE.   
 Overall, fluorous chemistry incorporates standard solution phase reaction conditions and 
analytical techniques with simplified and highly selective purification procedures. Due to these 
properties, fluorous supports have successfully been exploited in combinatorial library synthesis 
and synthetic methods development. These efforts have been thoroughly detailed in several 
reviews,
88
 and thus the current discussion will highlight only a few examples to illustrate the 
power of the fluorous phase platform.   
4.1.2. Curran’s and Zhang’s Fluorous Combinatorial Synthesis of Mappicine Analogs  
 Nothapodytine B (4.1, Figure 4.2) is a natural product isolated from Nothapodytes 
foetida that displays potent cytotoxicity in human KB lines
92
 and antiviral activity against 
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HSV-1, HSV-2, and human cytomegalovirus (HCMV).
93
 The molecule is an oxidized analog of 
the Mappa foetida alkaloid mappicine (4.2)
94
 and a decarboxylated derivative of camptothecin 
(4.3), an effective DNA topoisomerase I inhibitor.
95
 In the early 2000s, the Curran and Zhang 
groups reported the fluorous mixture synthesis of a 560-member mappicine analog library 
(Scheme 4.1).
96
 The team employed a fluorous tagging system, where seven pyridinyl alcohols 




The tagged molecules were then mixed together and subjected to consecutive 
iodination/demethylation reactions to generate tagged pyridones (4.6).
96
 After splitting the 
resulting mixture into eight portions, N-alkylation with eight distinct propargyl bromides was 
conducted in parallel (4.6 → 4.7). The following eight pools were then separated into 10 portions 
for parallel radical tandem cyclization with 10 isonitriles to produce 80 mixtures of fluorous 
tagged mappicine analogs (4.7 → 4.8). Subsequently, fluorous HPLC was used to isolate the 
individual components from each pool on the basis of the fluorine content the tags provide. A 
total of 560 pure mappicine derivatives (4.9) were obtained after silyl deprotection.  
 Curran’s and Zhang’s combinatorial synthesis of mappicine analogs demonstrates that 
fluorous phase techniques can be leveraged to separate individual, pure products after a reaction 
process involving a mixture of organic molecules. Generally, solution phase reactions performed 
on organic mixtures are highly efficient and demonstrate favorable reaction kinetics. 
Nevertheless, the overall procedures can be exceedingly difficult to achieve due to time-
consuming challenges that emerge with the analysis, identification, and separation of each 
mixture component. The group’s fluorous supported route bypassed these dilemmas and granted 
access to a pure library of compounds that was adequately evaluated in biological systems.
98
 
Moreover, the strategy accommodated key reaction steps that could not be optimized on a solid-
phase platform.
96
     
4.1.3. Zhang’s Fluorous Synthetic Method Towards Novel Fused Heterocyclic Ring Systems 
 Zhang and co-workers utilized a fluorous phase approach to generate three novel triaza 
tricyclic and tetracyclic ring systems.
99
 The reaction method began with the synthesis of proline 
derivative 4.13 from a one-pot, three-component [3 + 2] cycloaddition between a fluorous amino 
ester (4.10), an N-alkylmaleimide (4.11), and a benzaldehyde (4.12, Scheme 4.2). This process 
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was conducted under conventional or microwave heating and provided highly stereoselective 
bicyclic products after FSPE. The proline analogs obtained were then used for diversity-oriented 
synthesis (DOS) to produce hydantoin-, piperazinedione-, and benzodiazepine-fused ring 
systems 4.15, 4.17, and 4.19 respectively (Scheme 4.3). The heterocyclic structures possessed 





addition, each compound contained privileged moieties which exhibit a wide range of 
pharmaceutical utility.
40a,100 
 Synthetically speaking, the hydantoin-fused molecules 4.15 were generated by first 
reacting intermediates 4.13 with phenylisocyanate in the presence of catalytic amounts of 
4-dimethylaminopyridine (DMAP) to provide 4.14.
99
 Next, compounds 4.14 were subjected to 
base-promoted detagging and cyclization under microwave irradiation to give the final products. 
Moving forward, the synthesis of the piperazinedione tricyclic species 4.17 was accomplished by 
acylation of 4.13 with chloroacetylchloride, followed by substitution with amines to create 4.16.  
The linker cleavage/cyclization reactions on 4.16 were then promoted with 
1,8-diazabicyclo[4.3.0]non-5-ene (DBU) using microwave irradiation. Finally, the 
benzodiazepine scaffolds 4.19 were produced with a three-step sequence involving the 
acylation/reduction of pyrrolidine 4.13 to intermediate 4.18, followed by cyclative linker 
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cleavage in DBU to give the final derivatives. All of the intermediate reactions were purified by 
FSPE, while the final steps for each analog class required FSPE and HPLC for maximum purity. 
The Zhang group would further apply the chemistry developed for 4.15 and 4.19 in the fluorous 
mixture synthesis of heterocyclic combinatorial libraries.
101 
4.2. The Fluorous Phase Synthesis of αHTs 
As previously reviewed, we recently discovered a three-component oxidopyrylium 
cycladdition that generates new oxabicyclic compounds through alcohol incorporation (Scheme 
4.4A).
71
 Additionally, benzyl alcohol-derived oxabicyclic intermediates produced from this 
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reaction can be directly converted to αHTs when subjected to methanesulfonic acid (Scheme 
4.4B). Considering this information, we developed a solid-phase synthesis of αHTs utilizing 
polystyrene-supported benzyl alcohol (Scheme 4.4C).
82
 The method is extremely time efficient 
(i.e. a batch of 8 molecules produced over a 24 hour period) and provides compounds with assay-
ready purity. However, improvements to the system are necessary to reach its full potential as a 
combinatorial technique for αHT synthesis. First, though yields for the process are practical for 
biological screening, they are substantially low overall (i.e. 5-20% yield for 9 substrates). 
Secondly, the platform does not permit the modification of resin-bound intermediates, as 
conditions for both Suzuki coupling and trifluoroacetic acid (TFA) deprotection cause 
unintended cleavage (results not reported).  
In order to address the issues corresponding with solid-phase synthesis, we turned our 
attention to a fluorous phase approach. As outlined above, fluorous chemistry allows the 
successful integration of solution phase reaction conditions and provides the ability to monitor 




 Moreover, in relation to traditional organic synthesis, fluorous tagged compounds 
can be purified easily and efficiently by exclusive techniques based on fluorine-fluorine 
interactions (i.e. FLLE and FSPE).
88-91
 The following describes our attempts at synthesizing 
αHTs by employing fluorous supported synthesis. 
4.2.1. Fluorous Tag Incorporation and Cleavage 
The integration of fluorous phase chemistry into our synthetic route poses three 
challenges: 1) verify that fluorous tagged alcohols could successfully be incorporated into 
oxabicyclic products, 2) assess how well the tagged compounds work with fluorous separation 
techniques, and 3) demonstrate the capability to remove the tagged segment and form the final 
product. Our studies began with the preparation of the fluorous tagged benzyl alcohol derivative 
4.27, which can be generated in high yields through a previously reported approach.
102
 
Generally, the three-component oxidopyrylium cycloaddition is conducted under sealed 
conditions with a surplus of alcohol (5 equivalents in relation to monomeric ylide) to drive the 
incorporation.
71 
Considering the large molecular weight of 4.27, slight modifications to our 
originally optimized procedure were required (Scheme 4.5A). For instance, the quantity of 
alcohol was reduced (i.e. stoichiometric with monomeric ylide) to avoid excessive use of starting 
material. Also, the incorporation time was increased to accommodate the lower alcohol 
concentration. We were able to synthesize the fluorous tagged oxabicyclic compound 4.28a with 
a 34% yield using these adjustments, which is consistent for aryl-containing products obtained 
through the previously described method. 
 
However, when larger scale experiments were performed under these sealed conditions, 
reaction times were significantly increased, yielding little to no incorporation after 6 days. 




 we speculated that the lack of conversion was due to the increased generation of 
MeOH that accompanies the scaled up procedure. Since MeOH is more prevalent and trapped 
within the reactor, the equilibrium of the alcohol incorporation is driven significantly from the 
fluorous tagged ylide back to 4.21. In order to remove the MeOH byproduct from the reaction, 
the solvent system was changed to a 2:1 mixture of carbon tetrachloride (CCl4) and 
perfluoromethylcyclohexane (C7F14) and the vessel was exposed to a light stream of argon 
(Scheme 4.5B). This solvent combination was chosen not only for its ability to dissolve the 
quantities of fluorous tagged alcohol necessitated by the reaction but for its higher boiling point 
(76 
o
C for both solvents) that supersedes MeOH (64.7 
o
C). The boiling temperature, along with 
the argon flow, allows for the evaporation of MeOH without drying out the reaction. Thus, the 
equilibrium of the alcohol incorporation is shifted towards the product and the reaction time is 
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decreased. With these scale-up alterations, compound 4.28a was generated in a 38% yield in 
approximately 2 days, demonstrating a similar yield to its smaller scale counterpart.   
Moving forward, we wanted to test if the newly obtained oxabicyclic product could be 
purified by fluorous phase separation techniques. Since the fluorine content of 4.28a (<50%) is 
not acceptable for FLLE,
89
 we chose FSPE as our starting point. Compound 4.28a was purposely 
contaminated with the non-fluorinated derivative 4.29a and loaded onto a 4 gram column of 
standard tridecafluoro functionalized silica gel (SiliaBond
®
 Tridecafluoro, Figure 4.3). 
Following a typical FSPE procedure,
91
 4.29a was extracted with 80% MeOH in water and 4.28a 
was retrieved with acetone. Overall, 94% of 4.28a and 93% of 4.29a were recovered, proving 
that FSPE can be used to purify the fluorous tagged oxabicycles. 
After demonstrating that it is possible to incorporate fluorous tagged alcohols into our 
oxabicyclic products and purify them with fluorous extraction, we directed our attention towards 
193  
the ring-opening/debenzylation phase of 4.28a to αHT 4.24a. In our previous report,
71
 the 
benzyl-derived oxabicycle 4.23a underwent both ring-opening and debenzylation when exposed 
to liquid- and solid-phase methanesulfonic acid. Upon subjecting 4.28a to these conditions, we 
only observed the ring-opening product, as fluorous tagged tropolone 4.30a was isolated in 
quantitative yields (Scheme 4.6). The fluorous segment was removed upon returning to our 
original demethylation procedure (i.e. HBr in acetic acid), and a crude mixture of αHT 4.24a and 
fluorous tagged impurities was obtained. Considering the high fluorine content of the benzylated 
byproducts (>50%), both FSPE and FLLE were successfully used to purify the final product. 
With regard to the latter purification method, a 50% solution of methoxyperfluorobutane 
(HFE-7100) in C7F14 proved very effective in separating unwanted contaminants from the αHT 
(refer to Supp. Info.). Compound 4.24a was obtained in 85% yield after FSPE and 95% yield 
after FLLE. 
4.2.2. The Chemical Modification of Fluorous Tagged Oxabicyclic and Tropolone Intermediates  
We found the result described above very promising since it indicates that the electron 
deficient nature of the fluorous tag introduces stability to our intermediates in harsh media. The 
added stabilization would allow us to perform modification at multiple stages of our synthetic 
route, unlike in the case of solid-phase synthesis. To test this hypothesis, we synthesized a pair of 
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fluorous tagged oxabicycles (4.28j and 4.28k) with functional handles to attempt a series of 
experiments involving metal catalyzed cross coupling and amide coupling. 
Initially, various palladium catalyzed Suzuki reactions, including systems with 
Pd(OAc)2/JPhos or Pd(PPh)4, were performed on compound 4.28j with benzyl and naphthyl 
boronic acids to complete conversion. The resulting oxabicycles were subjected to ring-
opening/debenzylation conditions, and the corresponding αHTs were synthesized and confirmed 
through NMR analysis (results not shown). Unfortunately, pure final compounds could not be 
obtained with these procedures due to the presence of phosphine derived byproducts. Such 
impurities are not very soluble in the nonfluorous mobile phase of FSPE (80% MeOH in water or 
70% ACN in water), and hence contaminate the fluorous eluent (acetone or MeOH) to the 
detriment of subsequent reaction purity.  
In order to bypass this issue, we moved towards Suzuki conditions that utilize water 
soluble SPhos as the activating ligand (Scheme 4.7).
27b
 The phosphine byproducts were 
significantly removed from the intermediate but large amounts of solvent were still necessary 
during FSPE to achieve adequate purity (refer to Supp. Info.). However, the resulting bisphenyl 
oxabicyclic intermediate was successfully converted to pure αHT 4.24j after ring-
opening/debenzylation. Studies on making purification for metal-catalyzed cross-coupling 
reactions on our fluorous tagged oxabicyclic products more efficient are currently ongoing. 
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Nevertheless, this data demonstrates that modification through a fluorous phase approach is more 
tolerated than our previously reported solid-phase synthesis.  
Moving forward to amide coupling reactions, compound 4.28k was used as a starting 
point to generate fluorous tagged intermediates with carboxylic acid functionalities (Scheme 
4.8). Through a simple reaction sequence involving an acid-mediated deprotection, followed by a 
ring-opening, 4.28k was converted to oxabicycle 4.28l and tropolone 4.30l near quantitatively. 
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Each of these carboxylic acid derivatives was reacted with piperidine in the presence of PyBOP 
and N,N-diisopropylethylamine (DIPEA) to either produce compound 4.28m in 59% yield or 
4.30m in 84% yield after FSPE and hexane wash (Scheme 4.9). The corresponding αHT was 
then obtained by two different paths: 1) ring-opening/debenzylation of oxabicycle 4.28m and 2) 
debenzylation of tropolone 4.30m. Both steps were purified by FLLE to separate the fluorous 
tagged impurities from the final product 4.24m, demonstrating a divergent synthetic pathway to 
access an amide-derived αHT with fluorous phase chemistry.  
Taking into account that a secondary amine was used during our initial amide 
modification experiments, we tested if primary amines could also undergo a divergent approach 
to αHTs (Scheme 4.10). When oxabicycle 4.28l was subjected to PyBOP coupling conditions 
with 1-naphthylmethylamine, major decomposition was observed and the anticipated amide 
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could not be obtained after FSPE. On the other hand, tropolone 4.30l was successfully converted 
to the corresponding amide-derivative 4.30n using the PyBOP procedure outlined above and 
taken further to αHT 4.24n in high yields for both steps. Thus, even though the oxabicycle route 
is limited to more sterically hindered secondary amines, the tropolone pathway can be used to 
achieve the coupling of both types of amines. 
4.3. Conclusion 
In summary, we have demonstrated the first fluorous phase synthesis of αHTs utilizing 
three-component oxidopyrylium cycloaddition chemistry. In a prior report, we have shown that 
this reaction could be leveraged towards incorporation of solid-phase resins.
82
 Though the 
method was time efficient and yielded assay-ready compounds, our solid-supported synthesis 
resulted in low yields and an inability to modify intermediates while attached to the resin. By 
incorporating fluorous tags instead of solid supports, we have significantly improved reaction 
output and generated intermediates that can undergo modification through metal catalyzed cross 
coupling and amide coupling. Studies are currently ongoing to fully optimize this platform in 
order to make it a combinatorial technique for αHTs. 
4.4. Experimental and Supporting Information 
General Information: All starting materials and reagents were purchased from commercially 
available sources and used without further purification, with the exception of CH2Cl2, which was 








C NMR shifts were 
measured using the solvent residual peak as the internal standard and reported as follows: 
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet 
of doublets, q = quartet, m = multiplet), coupling constant (Hz), integration. Infrared (IR) 
spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w). Mass 
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spectra were recorded on a spectrometer by the electrospray ionization (ESI) technique with a 
time-of-flight (TOF) mass analyzer. Microwave reactions were performed via the Biotage
®
 
Initiator (external IR temperature sensor). Where noted, reaction products were purified via silica 
gel chromatography using a Biotage
®
 Isolera Prime, with Biotage
®
 SNAP Ultra 10 g or 25 g 
cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane. Fluorous solid-phase 
extraction (FSPE) was performed using columns packed with SiliaBond
®
 Tridecafluoro silica 
gel. 
Synthesis of Fluorous Tagged 3-Benzyloxy-8-Oxabicyclo[3.2.1]octenes: 
5-Methyl-3-((4-(perfluorooctyl)benzyl)oxy)-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one 
(4.28a). Method A. Dimer 4.26 (24 mg, 0.0856 mmol), benzyl alcohol 4.27 (91 mg, 0.172  mmol, 
2 equiv.), and CH2Cl2 (0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage
®
 
microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicon bath 
oil for 36 h. Phenyl acetylene (378 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and 
the reaction mixture was subjected to microwave irradiation at 100 ºC for 1 h. The reaction was 
then immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 20% 
EtOAc/hexane gradient over 23 column volumes), giving 4.28a as a yellow oil (43 mg, 34% 
yield). Method B. Dimer 4.26 (200 mg, 0.714 mmol) and benzyl alcohol 4.27 (751 mg,           
1.43 mmol, 2 equiv.) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,  
10-20 mL) and the vessel was purged with argon (3x). Carbon tetrachloride (2.75 mL) and 
perfluoromethylcyclohexane (1.38 mL) were added to the sealed reactor, and the reaction 
mixture was heated to 60 ºC in silicon bath oil for 48 h under argon. Phenyl acetylene (3.14 mL, 
28.6 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture was subjected to 
microwave irradiation at 100 ºC for 2.5 h. The reaction mixture was evaporated and purified by 
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column chromatography (silica (25 g), 0% EtOAc/hexane to 15% EtOAc/hexane gradient over 
17 column volumes), giving 4.28a as a yellow oil (401.9 mg, 38% yield). FSPE Protocol A. A 
Biotage
®
 SNAP Ultra 10 g cartridge was filled with SiliBond
®
 Tridecafluoro silica gel (4 g) and 
preconditioned with 50% MeOH in H2O. Compound 4.28a (46.4 mg, 0.063 mmol) was 
contaminated with 4.29a (13.5 mg, 0.056 mmol), and the mixture was loaded onto the cartridge 
in CHCl3. The nonfluorous material was provided by elution with 80% MeOH in H2O (40 mL), 
while the fluorous component was obtained by elution with acetone (40 mL). The resulting 
fractions were then concentrated, giving 4.28a as a yellow oil (43.4 mg, 94% recovery) and 
4.29a as a white solid (12.6 mg, 93% recovery). The cartridge was washed with MeOH (40 mL) 
and acetone (40 mL) prior to reuse, and it was recycled up to 30 times. The 1H NMR for 4.29a 
was consistent with previously reported data.
49a 
Characterization of 4.28a. Rf = 0.27 in 15% 
EtOAc in hexanes. IR (thin film, KBr): 3060 (w), 2981 (w), 2935 (w), 1712 (s), 1606 (s), 1492 





H NMR (400 MHz, CDCl3): δ 7.58 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H),   
7.38 – 7.31 (m, 3H), 7.20 – 7.15 (m, 2H), 6.29 (d, J = 2.4 Hz, 1H), 6.24 (s, 1H), 5.02                
(d, J = 2.5 Hz, 1H), 4.97 (d, J = 12.7 Hz, 1H), 4.85 (d, J = 12.7 Hz, 1H), 1.64 (s, 3H). 
19
F NMR 
(376 MHz, CDCl3): δ -80.8 (t, J = 9.9 Hz, 3F), -110.7 (t, J = 14.5 Hz, 2F), -121.1 – -121.4      
(m, 2F), -121.7 – -122.1 (m, 6F), -122.56 – -122.89 (m, 2F), -126.0 – -126.2 (m, 2F). 
13
C NMR          
(100 MHz, CDCl3): δ 189.7 (s), 158.8 (s), 144.6 (s), 140.0 (s), 133.0 (s), 128.9 (s), 128.9                  
(t,  J = 24.4 Hz), 128.8 (s), 127.4 (s), 127.4 (t, J = 6.4 Hz), 126.0 (s), 123.2 (s), 122.0 (s),       






dien-2-one (4.28j). Dimer 4.26 (200 mg, 0.714 mmol) and benzyl alcohol 4.27 (751 mg,        
1.43 mmol, 2 equiv.) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,  
10-20 mL), and the vessel was purged with argon (3x). Carbon tetrachloride (2.75 mL) and 
perfluoromethylcyclohexane (1.38 mL) were added to the sealed reactor, and the reaction 
mixture was heated to 60 ºC in silicon bath oil for 36 h under argon. 1-Bromo-3-ethynylbenzene 
(1.72 mL, 14.3 mmol, 20 equiv.) was added to the sealed tube, and the reaction mixture was 
subjected to microwave irradiation at 100 ºC for 3 h. The reaction mixture was evaporated and 
purified by column chromatography (silica (25 g), 0% EtOAc/hexane to 15% EtOAc/hexane 
gradient over 27 column volumes), giving 4.28j as a yellow oil (366.7 mg, 32% yield). Due to 
the high cost of 1-bromo-3-ethynylbenzene, fractions containing it were also concentrated  
(2.029 g, 87% recovery (2.321 g would be 100% theoretical yield of unreacted product)).          
Rf = 0.29 in 15% EtOAc in hexanes. IR (thin film, KBr): 3064 (w), 2982 (w), 2936 (w), 1713 
(s), 1605 (s), 1588 (m), 1558 (m), 1473 (m), 1338 (m), 1295 (s), 1210 (s), 1151 (s), 1059 (m), 




H NMR (400 MHz, CDCl3): δ 7.58 (d, J = 8.3 Hz, 2H),          
7.52 – 7.44 (m, 3H), 7.38 – 7.35 (m, 1H), 7.24 – 7.18 (m, 1H), 7.09 – 7.05 (m, 1H), 6.34           
(d, J = 2.4 Hz, 1H), 6.23 (s, 1H), 5.02 (d, J = 2.5 Hz, 1H), 4.96 (d, J = 12.6 Hz, 1H), 4.85         
(d, J = 12.6 Hz, 1H), 1.63 (s, 3H). 
19
F NMR (376 MHz, CDCl3): δ -80.8 (t, J = 9.5 Hz, 
3F), -110.7 (t, J = 14.5 Hz, 2F), -121.2 (bs, 2F), -121.6 – -122.1 (m, 6F), -122.6 – -122.9 (m, 2F), 
-126.0 – -126.3 (m, 2F). 
13
C NMR (100 MHz, CDCl3): δ 189.3 (s), 157.5 (s), 144.7 (s), 139.9 
(s), 135.1 (s), 131.8 (s), 130.3 (s), 129.1 (s), 129.0 (t, J = 24.3 Hz), 127.4 (s), 127.4                    
(t, J = 6.5 Hz), 124.8 (s), 124.5 (s), 123.0 (s), 121.5 (s), 86.4 (s), 86.1 (s), 68.8 (s), 22.0 (s).
 
HRMS (ESI+): m/z calc’d for C29H16BrF17O3Na
+
: 836.9904. Found: 836.9907. 
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tert-Butyl 5-methyl-2-oxo-3-((4-(perfluorooctyl)benzyl)oxy)-8-oxabicyclo[3.2.1]octa-3,6- 
diene-6-carboxylate (4.28k). Dimer 4.26 (200 mg, 0.714 mmol) and benzyl alcohol 4.27      
(751 mg, 1.43 mmol, 2 equiv.) were placed in a sealed tube reactor (Biotage
®
 microwave 
reaction vial, 10-20 mL), and the vessel was purged with argon (3x). Carbon tetrachloride    
(2.75 mL) and perfluoromethylcyclohexane (1.38 mL) were added to the sealed reactor, and the 
reaction mixture was heated to 60 ºC in silicon bath oil for 48 h under argon. tert-Butyl 
propiolate (1.96 mL, 14.3 mmol, 20 equiv.) was added to the sealed tube, and the reaction 
mixture was subjected to microwave irradiation at 100 ºC for 1 h. The reaction mixture was 
evaporated and purified by column chromatography (silica (25 g), 0% EtOAc/hexane to 10% 
EtOAc/hexane gradient over 24 column volumes), giving 4.28k as a white solid (550.5 mg, 51% 
yield). MP = 109-112 ºC. Rf = 0.21 in 10% EtOAc in hexanes. IR (thin film, KBr): 3059 (w), 
2982 (w), 2938 (w), 1703 (s), 1615 (m), 1604 (m), 1452 (w), 1370 (m), 1329 (m), 1300 (m), 




H NMR (400 MHz, CDCl3): δ 
7.58 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 6.98 (d, J = 2.5 Hz, 1H), 6.15 (s, 1H), 5.01   
(d, J = 2.5 Hz, 1H), 4.86 (d, J = 12.5 Hz, 1H), 4.79 (d, J = 12.5 Hz, 1H), 1.72 (s, 3H), 1.48        
(s, 9H). 
19
F NMR (376 MHz, CDCl3): δ -80.7 (t, J = 9.9 Hz, 3F), -110.7 (t, J = 14.5 Hz, 2F),      
-121.1 – -121.3 (m, 2F), -121.7 – -122.0 (m, 6F), -122.5 – -122.8 (m, 2F), -126.0 – -126.2       
(m, 2F). 
13
C NMR (100 MHz, CDCl3): δ 188.7 (s), 162.2 (s), 151.1 (s), 143.8 (s), 139.9 (s), 
137.6 (s), 128.9 (t, J = 24.4 Hz), 127.5 (s), 127.4 (t, J = 6.4 Hz), 121.9 (s), 86.0 (s), 85.6 (s), 82.4 
(s), 68.6 (s), 28.2 (s), 21.4 (s). HRMS (ESI+): m/z calc’d for C28H21F17O5Na
+
: 783.1010. Found: 
783.1011. 
5-Methyl-2-oxo-3-((4-(perfluorooctyl)benzyl)oxy)-8-oxabicyclo[3.2.1]octa-3,6-diene-6-
carboxylic acid (4.28l). Oxabicycle 4.28k (435.8 mg, 0.573 mmol) and 50% trifluoroacetic acid 
in CH2Cl2 (2.2 mL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial,      
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2-5 mL), and the reaction mixture was subjected to microwave radiation at 70 ºC for 2 min. The 
organic layer was concentrated under reduced pressure and then subjected to azeotropic removal 
with CH2Cl2 (5 x 2 mL), resulting in a yellowish solid. The solid was washed with hexane         
(5 x 4 mL) and dried under vacuum to give 4.28l as an off-white solid (396.7 mg, >95% yield). 
MP = 144-146 ºC. Rf = 0.25 in 10% MeOH in CH2Cl2. IR (thin film, KBr): 3070 (w), 2989 (w), 
2867 (br), 1708 (m), 1676 (s), 1616 (m), 1605 (m), 1422 (w), 1335 (m), 1280 (m), 1199 (s), 1147 




H NMR (400 MHz, CDCl3): δ 7.59                 
(d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 2.5 Hz, 1H), 6.17 (s, 1H), 5.10           
(d, J = 2.5 Hz, 1H), 4.84 (d, J = 12.3 Hz, 1H), 4.79 (d, J = 12.3 Hz, 1H), 1.77 (s, 3H). 
19
F NMR 
(376 MHz, CDCl3): δ -80.9 (t, J = 9.9 Hz, 3F), -110.8 (t, J = 14.4 Hz, 2F), -121.3 (bs, 2F),          
-121.8 – -122.1 (m, 6F), -122.8 (bs, 2F), -126.0 – -126.7 (m, 2F). 
13
C NMR (100 MHz, CDCl3): 
δ 188.1 (s), 167.9 (s), 148.9 (s), 143.9 (s), 142.3 (s), 139.6 (s), 129.1 (t, J = 24.3 Hz), 127.6 (s), 
127.4 (t, J = 6.4 Hz), 121.5 (s), 86.3 (s), 85.5 (s), 68.8 (s), 21.3 (s). HRMS (ESI+): m/z calc’d 
for C24H13F17O5Na
+
: 727.0384. Found: 727.0387. 
5-Methyl-3-((4-(perfluorooctyl)benzyl)oxy)-6-(piperidine-1-carbonyl)-8-oxabicyclo[3.2.1] 
octa-3,6-dien-2-one (4.28m). A solution of oxabicycle 4.28l (60 mg, 0.0852 mmol), PyBOP 
(48.8 mg, 0.0937 mmol, 1.1 equiv.), and DIPEA (32.6 μL, 0.187 mmol, 2.2 equiv.) in CH2Cl2 
(0.04 M, 2 mL) was stirred at room temperature for 20 min in a sealed tube reactor (Biotage
®
 
microwave reaction vial, 2-5 mL). Piperidine (9.3 μL, 0.0937 mmol, 1.1 equiv.) was then added 
to the sealed vessel, and the reaction mixture was subjected to microwave radiation at 85 ºC for  
5 min. The mixture was concentrated under reduced pressure and purified by FSPE as described 
in Protocol A. The acetone layer was evaporated, producing a yellow solid. The solid was 
washed with hexane (5 x 2 mL) to give 4.28m as a white solid (38.7 mg, 59% yield).               
203  
MP = 173-175 ºC. Rf = 0.29 in 40% EtOAc in hexanes. IR (thin film, KBr): 3070 (w), 2942 
(m), 2862 (m), 1711 (s), 1609 (s), 1445 (s), 1287 (s), 1212 (s), 1151 (s), 1089 (m), 1026 (m), 989 




H NMR (400 MHz, CDCl3): δ 7.58                  
(d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 6.35 (s, 1H), 6.29 (d, J = 2.4 Hz, 1H), 5.11           
(d, J = 2.4 Hz, 1H), 4.85 (d, J = 12.2 Hz, 1H), 4.80 (d, J = 12.2 Hz, 1H), 3.67 – 3.45 (m, 4H), 
1.76 – 1.66 (m, 2H), 1.65 – 1.49 (m, 7H). 
19
F NMR (376 MHz, CDCl3): δ -80.7 (t, J = 9.9 Hz, 
3F), -110.7 (t, J = 14.4 Hz, 2F), -121.1 – -121.3 (m, 2F), -121.7 – -122.1 (m, 6F), -122.7 (bs, 2F), 
-125.8 – -126.5 (m, 2F). 
13
C NMR (100 MHz, CDCl3): δ 188.3 (s), 163.6 (s), 150.7 (s), 143.9 
(s), 140.1 (s), 128.8 (t, J = 24.5 Hz), 127.8 (s), 127.8 (s), 127.3 (t, J = 6.5 Hz), 123.6 (s), 87.4 (s), 
87.1 (s), 68.7 (s), 47.9 (s), 42.9 (s), 27.0 (s), 25.8 (s), 24.7 (s), 20.7 (s). HRMS (ESI+): m/z 
calc’d for C29H23F17NO4
+
: 772.1350. Found: 772.1352. 
Synthesis of Fluorous Tagged Benzyloxy Tropolones: 
2-Hydroxy-5-methyl-7-((4-(perfluorooctyl)benzyl)oxy)-4-phenylcyclohepta-2,4,6-trien-1-
one (4.30a). To a solution of 4.28a (135.2 mg, 0.184 mmol) in CH2Cl2 (0.16 M, 1.15 mL) was 
added methanesulfonic acid (477 μL, 7.36 mmol, 40 equiv). The reaction mixture was stirred at 
room temperature for 1 h, at which time it was quenched with phosphate buffer (pH 7, 0.1 M,     
5 mL) and extracted with CHCl3 (3 x 5 mL). The organic layer was washed with brine (15 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield a golden brown 
solid. This solid was washed with hexane (5 x 2 mL) and dried under vacuum to give 4.30a as a 
light brown solid (131.6 mg, >95% yield). MP = Decomposes at 155 ºC. IR (thin film, KBr): 
3220 (br), 3029 (w), 2917 (w), 2858 (w), 1575 (m), 1564 (m), 1473 (m), 1384 (w), 1332 (m), 




H NMR (400 MHz, 
CDCl3): δ 7.67 (d, J = 8.6 Hz, 2H), 7.63 (d, J = 8.7 Hz, 2H), 7.46 – 7.35 (m, 4H), 7.31 (s, 1H), 
204  
7.24 – 7.20 (m, 2H), 5.39 (s, 2H), 2.18 (s, 3H). 
19
F NMR (376 MHz, CDCl3): δ -80.8                
(t, J = 9.9 Hz, 3F), -110.6 (t, J = 14.3 Hz, 2F), -121.2 (bs, 2F), -121.6 – -122.1 (m, 6F),                
-122.7 (bs, 2F), -126.0 – -126.2 (m, 2F).
 13
C NMR (100 MHz, CDCl3): δ 169.5 (s), 160.3 (s), 
156.6 (s), 145.2 (s), 143.5 (s), 140.7 (s), 135.0 (s), 128.9 (t, J = 24.3 Hz), 128.7 (s), 128.2 (s), 
127.9 (s), 127.6 (s), 127.6 (s), 127.5 (t, J = 6.5 Hz), 122.3 (s), 71.0 (s), 26.5 (s). HRMS (ESI+): 
m/z calc’d for C29H18F17O3
+
: 737.0979. Found: 737.0982. 
6-Hydroxy-2-methyl-5-oxo-4-((4-(perfluorooctyl)benzyl)oxy)cyclohepta-1,3,6-triene-1-
carboxylic acid (4.30l). To a solution of 4.281 (116.1 mg, 0.165 mmol) in CH2Cl2 (0.1 M,    
1.42 mL) was added trifluoromethanesulfonic acid (58.2 μL, 0.659 mmol, 4 equiv). The reaction 
mixture was stirred at room temperature for 30 min, at which time it was quenched with 
phosphate buffer (pH 7, 1 M, 5 mL). The CH2Cl2 was drained and the remaining residue was 
extracted with EtOAc (3 x 5 mL). All organics were collected, dried over Na2SO4, filtered, and 
concentrated under reduced pressure to give a yellow solid. The solid was washed with 50% 
CH2Cl2 in hexanes (6 x 2 mL) and dried under vacuum to give 4.30l as a light yellow solid 
(107.3 mg, 92% yield). MP = 163-166 ºC.  IR (thin film, KBr): 3442 (br), 1699 (m), 1621 (w), 
1570 (m), 1482 (w), 1382 (w), 1372 (w), 1299 (m), 1230 (s), 1201 (s), 1149 (s), 1111 (m), 1051 




H NMR (400 MHz, Acetone): δ 7.85 (d, J = 8.2 Hz, 2H), 
7.77 (d, J = 8.3 Hz, 2H), 7.57 (s, 1H), 7.49 (s, 1H), 5.50 (s, 2H), 2.56 (s, 3H). 
19
F NMR         
(376 MHz, Acetone): δ -81.6 (t, J = 10.1 Hz, 3F), -110.7 (t, J = 14.5 Hz, 2F), -121.6 – -121.9         
(m, 2F), -122.2 – -122.6 (m, 6F), -123.2 (bs, 2F), -126.6 – -126.9 (m, 2F).
 13
C NMR (100 MHz, 
Acetone): δ 171.8 (s), 170.2 (s), 160.2 (s), 159.2 (s), 142.5 (s), 137.1 (s), 133.8 (s), 128.9 (s), 
128.6 (t, J = 24.3 Hz), 127.9 (t, J = 6.5 Hz), 125.9 (s), 117.0 (s), 71.0 (s), 25.4 (s). HRMS 
(ESI+): m/z calc’d for C24H14F17O5
+
: 705.0564. Found: 705.0570. 
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2-Hydroxy-5-methyl-7-((4-(perfluorooctyl)benzyl)oxy)-4-(piperidine-1-carbonyl)-
cyclohepta-2,4,6-trien-1-one (4.30m). A solution of tropolone 4.30l (50 mg, 0.071 mmol), 
PyBOP (40.6 mg, 0.0781 mmol, 1.1 equiv.), and DIPEA (27.2 μL, 0.156 mmol, 2.2 equiv.) in 
EtOAc (0.04 M, 1.67 mL) was stirred at room temperature for 20 min in a sealed tube reactor 
(Biotage
®
 microwave reaction vial, 2-5 mL). Piperidine (7.7 μL, 0.0781 mmol, 1.1 equiv.) was 
then added to the sealed vessel, and the reaction mixture was subjected to microwave radiation at 
85 ºC for 5 min. The reaction mixture was concentrated under reduced pressure and purified by 
FSPE as described in Protocol A. The acetone layer was evaporated, producing a yellow solid. 
The solid was washed with hexane (5 x 2 mL) and dried under vacuum to give 4.30m as a light 
yellow solid (45.8 mg, 84% yield). MP = 183-186 ºC. IR (thin film, KBr): 3175 (br), 2942 (w), 
2929 (w), 2861 (w), 1621 (m), 1568 (m), 1462 (m), 1450 (m), 1324 (m), 1202 (s), 1151 (s), 1135 




H NMR (400 MHz, CDCl3): δ 8.93 (bs, 1H), 
7.63 (s, 4H), 7.17 (s, 1H), 7.16 (s, 1H), 5.36 (d, J = 12.8 Hz, 1H), 5.32 (d, J = 12.8 Hz, 1H),   
3.84 – 3.75 (m, 1H), 3.69 – 3.61 (m, 1H), 3.27 – 3.13 (m, 2H), 2.34 (s, 3H), 1.76 – 1.62 (m, 4H), 
1.60 – 1.43 (m, 2H). 
19
F NMR (376 MHz, CDCl3): δ -80.7 (t, J = 9.9 Hz, 3F), -110.7                
(t, J = 14.4 Hz, 2F), -121.1 – -121.3 (m, 2F), -121.7 – -122.0 (m, 6F), -122.5 – -122.8 (m, 2F),    
-125.9 – -126.3 (m, 2F).
 13
C NMR (100 MHz, CDCl3): δ 170.4 (s), 168.6 (s), 161.2 (s), 157.2 
(s), 140.2 (s), 138.6 (s), 132.8 (s), 129.1 (t, J = 24.3 Hz), 127.6 (s), 127.5 (t, J = 6.5 Hz), 126.6 
(s), 116.2 (s), 71.0 (s), 47.9 (s), 42.6 (s), 26.6 (s), 25.7 (s), 24.5 (s), 24.2 (s). HRMS (ESI+): m/z 
calc’d for C29H23F17NO4
+
: 772.1350. Found: 772.1351. 
6-Hydroxy-2-methyl-N-(naphthalen-1-ylmethyl)-5-oxo-4-((4-(perfluorooctyl)benzyl)oxy) 
cyclohepta-1,3,6-triene-1-carboxamide (4.30n). A solution of tropolone 4.30l (51.7 mg,  
0.0734 mmol), PyBOP (42 mg, 0.0807 mmol, 1.1 equiv.), and DIPEA (28.1 μL, 0.161 mmol,  
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2.2 equiv.) in EtOAc (0.04 M, 1.67 mL) was stirred at room temperature for 20 min in a sealed 
tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL). 1-Naphthylmethylamine (11.8 μL, 
0.0807 mmol, 1.1 equiv.) was then added to the sealed vessel, and the reaction mixture was 
subjected to microwave radiation at 85 ºC for 5 min. The reaction mixture was concentrated 
under reduced pressure and purified by FSPE as described in Protocol A. The acetone layer was 
evaporated, producing a yellow solid. The solid was washed with hexane (5 x 2 mL) and ACN  
(5 x 2 mL) and dried under vacuum to give 4.30n as a light yellow solid (53.8 mg, 87% yield).                  
MP = 175-177 ºC. IR (thin film, KBr): 3239 (br), 3048 (w), 2923 (w), 1666 (m), 1541 (m), 
1471 (m), 1398 (w), 1373 (w), 1325 (m), 1212 (s), 1199 (s), 1146 (s), 1112 (m), 945 (w), 788 




H NMR (400 MHz, CDCl3): δ 8.10 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 8.0 Hz, 
1H), 7.81 (d, J = 8.1 Hz, 1H), 7.65 – 7.47 (m, 7H), 7.46 – 7.40 (m, 1H), 7.22 (s, 1H), 7.00         
(s, 1H), 6.40 (bs, 1H), 5.15 (s, 2H), 5.01 (s, 2H), 2.34 (s, 3H). 
19
F NMR (659 MHz, CDCl3): δ   
-80.7 (t, J = 9.4 Hz, 3F), -110.7 (t, J = 13.7 Hz, 2F), -121.2 (bs, 2F), -121.6 – -122.1 (m, 6F),       
-122.7 (bs, 2F), -126.1 (bs, 2F).
 13
C NMR (100 MHz, CDCl3): δ 170.2 (s), 169.1 (s), 160.6 (s), 
157.4 (s), 139.9 (s), 138.5 (s), 134.5 (s), 134.1 (s), 132.9 (s), 131.5 (s), 129.3 (s), 129.1              
(t, J = 26.6 Hz), 129.1 (s), 127.5 (t, J = 6.4 Hz), 127.5 (s), 127.4 (s), 127.0 (s), 126.4 (s), 126.1 
(s), 125.6 (s), 123.5 (s), 116.9 (s), 70.8 (s), 42.3 (s), 24.7 (s). HRMS (ESI+): m/z calc’d for 
C35H23F17NO4
+
: 844.1350. Found: 844.1353. 
Synthesis of α-Hydroxytropolones:  
2,7-Dihydroxy-4-methyl-5-phenylcyclohepta-2,4,6-trien-1-one (4.24a). FSPE Purification. 
Tropolone 4.30a (50 mg, 0.068 mmol) and 33% HBr in acetic acid (197 μL) were placed in a 
sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL), and the reaction mixture was 
heated to 120 ºC in silicon bath oil for 1 h. The reaction mixture was cooled to room 
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temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted with CHCl3    
(3 x 5 mL). The organic layer was evaporated under reduced pressure and purified by FSPE as 
described in Protocol A. The 80% MeOH in H2O layer was concentrated to yield 4.24a as a 
white solid (13.2 mg, 85% yield). The 
1
H NMR for 4.24a was consistent with previously 
reported data.
55
 FLLE Purification, Protocol A. Tropolone 4.30a (50.5 mg, 0.0686 mmol) and  
33% HBr in acetic acid (199 μL) were placed in a sealed tube reactor (Biotage
®
 microwave 
reaction vial, 2-5 mL), and the reaction mixture was heated to 120 ºC in silicon bath oil for 1 h. 
The reaction mixture was cooled to room temperature, quenched with phosphate buffer (pH 7, 
0.1 M, 5 mL), and extracted with CHCl3 (3 x 5 mL). The organic layer was dried over Na2SO4, 
filtered, and evaporated under reduced pressure to give a crude oil. The residue was taken up in 
ACN (2 mL) and washed with 50% HFE-7100 in perfluoromethylcyclohexane (5 x 2 mL). The 
ACN layer was concentrated to yield 4.24a as a brown oil (15.5 mg, >95% yield). The 
1
H NMR 
for 4.24a was consistent with previously reported data.
55 
 
4-([1,1'-Biphenyl]-3-yl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (4.24j). FSPE 
Protocol B. Compund 4.28j (36.1 mg, 0.0443 mmol), phenyl boronic acid (54 mg, 0.443 mmol, 
10 equiv.), water soluble SPhos (23 mg, 0.0443 mmol, 1 equiv.), K2CO3 (61.2 mg, 0.443 mmol, 
10 equiv.), Pd(OAc)2 (5 mg, 0.0222 mmol, 0.5 equiv.) and 33% ACN in H2O (0.01 M, 4.5 mL) 
were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL), and the 
reaction mixture was heated to 50 
o
C in silicon bath oil for 5 h. The reaction mixture was cooled 
to room temperature and immediately loaded to a Biotage
®
 SNAP Ultra 10 g cartridge that was 
filled with SiliBond
®
 Tridecafluoro silica gel (4 g) and preconditioned with 30% ACN in H2O. 
Any remaining residue in the reactor was loaded onto the column with CHCl3, and the 
nonfluorous material was provided by elution with ACN in H2O (0% ACN/H2O to 70% 
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ACN/H2O gradient over 12 column volumes) and MeOH in H2O (80% MeOH/H2O over             
3 column volumes). The fluorous component was obtained by elution with MeOH (100% MeOH  
over 5 column volumes) and the resulting fractions were then concentrated, giving 4.28o as a 
yellow oil (26.4 mg, 73% crude yield).  
To a solution of oxabicycle 4.28o (26.4 mg, 0.0325 mmol) in CH2Cl2 (0.1 M, 325 μL) 
was added trifluoromethanesulfonic acid (11.5 μL, 0.13 mmol, 4 equiv.). The reaction mixture 
was allowed to stir for 30 minutes, after which time it was quenched with phosphate buffer     
(pH 7, 0.1 M, 5 mL) and extracted with CHCl3 (3 x 5 mL). The organic layer was dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The crude mixture was then 
dissolved in 33% HBr in acetic acid (100 μL) and heated to 120 ºC for 1 h in a sealed tube 
reactor (Biotage
®
 microwave reaction vial, 2-5 mL). The reaction mixture was cooled to room 
temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted with CHCl3    
(3 x 5 mL). The organic layer was then dried over Na2SO4, filtered, and concentrated to give a 
crude oil. The residue was purified by FLLE according to Protocol A, giving 4.24j as a brown oil 
(8.9 mg, 90% yield over two steps). IR (thin film, KBr): 3248 (br), 3059 (w), 3033 (w), 2928 
(w), 2854 (w), 1525 (s), 1477 (m), 1450 (m), 1386 (s), 1277 (s), 1231 (s), 1131 (m), 1093 (m), 




H NMR (400 MHz, CDCl3): δ 7.65 – 7.59 (m, 4H), 7.55 (s, 
1H), 7.54 – 7.42 (m, 4H), 7.40 – 7.34 (m, 1H), 7.24 – 7.20 (m, 1H), 2.31 (s, 3H). 
13
C NMR           
(100 MHz, CDCl3): δ 167.3, 157.9, 156.6, 144.2, 143.8, 141.8, 140.6, 139.2, 129.2, 129.0, 
127.8, 127.3, 127.3, 127.2, 126.6, 124.5, 124.3, 26.6. HRMS (ESI+): m/z calc’d for C20H17O3
+
: 
305.1172. Found: 305.1176. 
2,7-Dihydroxy-4-methyl-5-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one (4.24m). 
Method A. To a solution of oxabicycle 4.28m (39.4 mg, 0.0511 mmol) in CH2Cl2 (0.1 M,        
511 μL) was added trifluoromethanesulfonic acid (18 μL, 0.204 mmol, 4 equiv.). The reaction 
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mixture was allowed to stir for 30 minutes, after which time it was quenched with phosphate 
buffer (pH 7, 0.1 M, 5 mL) and extracted with CHCl3 (3 x 5 mL). The organic layer was dried 
over Na2SO4, filtered, and concentrated under reduced pressure producing a brown residue. The 
crude mixture was then dissolved in 33% HBr in acetic acid (150 μL), and heated to 120 ºC for  
1 h in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL). The reaction mixture 
was cooled to room temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and 
extracted with CHCl3 (3 x 5mL). The organic layer was then dried over Na2SO4, filtered, and 
concentrated to give a crude oil. The residue was purified by FLLE according to Protocol A, 
giving 4.24m as a brown oil (10.4 mg, 77% yield over two steps). Method B. Tropolone 4.30m 
(40 mg, 0.0518 mmol) and 33% HBr in acetic acid (150 μL) were placed in a sealed tube reactor 
(Biotage
®
 microwave reaction vial, 2-5 mL), and the reaction mixture was heated to 120 ºC in 
silicon bath oil for 1 h. The reaction mixture was cooled to room temperature, quenched with 
phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted with CHCl3 (3 x 5 mL). The organic layer 
was dried over Na2SO4, filtered, and evaporated under reduced pressure to give a crude oil. The 
residue was purified by FLLE according to Protocol A, giving 4.24m as a brown oil (12.5 mg, 
92% yield). Characterization of 4.24m. IR (thin film, KBr): 3246 (br), 2940 (s), 2859 (m), 1627 
(s), 1541 (s), 1446 (s), 1389 (s), 1353 (s), 1265 (s), 1232 (s), 1136 (s) 1075 (m), 1026 (m), 912 




H NMR (400 MHz, CDCl3): δ 7.47 (s, 1H), 7.27 (s, 1H),            
3.86 – 3.77 (m, 1H), 3.70 – 3.62 (m, 1H), 3.25 – 3.13 (m, 2H), 2.41 (s, 3H), 1.77 – 1.44 (m, 6H). 
13
C NMR (100 MHz, CDCl3): δ 168.7, 168.2, 158.3, 157.8, 137.5, 137.0, 124.3, 118.6, 47.9, 
42.7, 26.5, 25.7, 24.5, 24.1. HRMS (ESI+): m/z calc’d for C14H18NO4
+




carboxamide (4.24n). Tropolone 4.30n (53 mg, 0.0628 mmol) and 33% HBr in acetic acid   
(185 μL) were placed in a sealed tube reactor (Biotage
®
 microwave reaction vial, 2-5 mL), and 
the reaction mixture was heated to 120 ºC in silicon bath oil for 1 h. The reaction mixture was 
cooled to room temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted 
with CHCl3 (3 x 5 mL). The organic layer was dried over Na2SO4, filtered, and evaporated under 
reduced pressure to give a crude oil. The residue was purified by FLLE according to Protocol A, 
giving 4.24n as a brown oil (18.8 mg, 89% yield). IR (thin film, KBr): 3263 (br), 3060 (m), 
2928 (m), 1697 (s), 1640 (s), 1536 (s), 1512 (s), 1441 (m), 1397 (s), 1248 (s), 1144 (m) 1091 




H NMR (400 MHz, Acetone): δ 8.28             
(d, J = 8.3 Hz, 1H), 8.02 (bs, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.64 – 7.46 
(m, 4H), 7.42 (s, 1H), 7.34 (s, 1H), 5.07 (d, J = 5.7 Hz, 2H), 2.42 (s, 3H). 
13
C NMR (100 MHz, 
Acetone): δ 169.9, 169.1, 159.7, 158.3, 138.7, 138.0, 135.2, 134.9, 132.5, 129.6, 129.1, 127.6, 
127.2, 126.8, 126.3, 124.7, 124.3, 119.9, 42.1, 24.3. HRMS (ESI+): m/z calc’d for C20H18NO4
+
: 
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